[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 107
1. Inoue T, Sada A, Mori T, Misago N, Narisawa Y: Congenital myofibroma of the skin mimicking a piloleiomyoma. J Cutan Pathol; 2010 Jun;37(6):678-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital myofibroma of the skin mimicking a piloleiomyoma.
  • Myofibroma is an uncommon benign soft tissue disorder, which is usually congenital or present in early infancy.
  • The other area contains either round or polygonal cells with slightly pleomorphic, hyperchromatic nuclei or small spindle cells typically arranged around a distinct hemangiopericytoma-like vascular pattern.
  • In the present case, the majority of the tumor was composed of the plump myoid spindle cells.
  • However, the tumor cells were not immunohistochemically positive for desmin.
  • Moreover, careful examination revealed a hemangiopericytoma-like vascular pattern characterized by the presence of high cellular areas with irregular vascular spaces.
  • [MeSH-major] Leiomyoma / pathology. Myofibroma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Desmin / metabolism. Diagnosis, Differential. Female. Humans. Infant. Skin / metabolism. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522159.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin
  •  go-up   go-down


2. Fröhlich E, Mack AF, Garbe C, Klessen C: Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. Br J Dermatol; 2005 Dec;153(6):1159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
  • METHODS: The distribution and colocalization of markers for proliferation, invasion, angiogenesis and motility of the tumour cells were investigated using antibodies directed against actin, cathepsin B (CatB), transforming growth factor-beta, vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen/Ki-67 and basic fibroblast growth factor (FGF-2).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Melanoma / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Cell Movement. Cell Proliferation. Diagnosis, Differential. Epidermal Growth Factor / metabolism. Humans. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307652.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


3. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • METHODS: Seventy-three patients of both genders with suspected malignant musculoskeletal lesions were studied by three-phase (vascular, tissue and delayed images) 99mTc-tectrofosmin scans.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


Advertisement
4. Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS: Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer; 2007 Dec 1;110(11):2519-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
  • BACKGROUND: A considerable body of evidence supports the concept that a significant number of cutaneous malignant melanomas progress through a precursor lesion or dysplastic melanocytic nevi (DN).
  • Tumor angiogenesis likely plays a critical role in early development of melanoma, and intermediate biomarkers of angiogenesis could be useful as chemoprevention and prognostic markers.
  • METHODS: Markers of angiogenesis that included expression of the vascular endothelial growth factor A (VEGF-A) and microvessel density counts (MVD) were evaluated in 13 prospectively collected benign nevi (BN) and 19 DN from 16 individuals and in a comparison group of 17 primary melanomas (16 archival samples and 1 prospective melanoma).
  • [MeSH-major] Melanoma / metabolism. Skin Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Disease Progression. Dysplastic Nevus Syndrome / metabolism. Female. Humans. Immunohistochemistry. Male. Microcirculation. Middle Aged. Neovascularization, Pathologic. Nevus / metabolism. Prospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17932890.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA27502
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


5. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G: How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol; 2010 Sep;63(3):361-74; quiz 375-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors.
  • Dermoscopy is a noninvasive tool that can be helpful in the diagnosis of nonpigmented skin tumors.
  • This is because dermoscopy permits the visualization of key vascular structures that are usually not visible to the naked eye.
  • Much work has concentrated on the identification of specific morphologic types of vessels that allow a classification into melanocytic versus nonmelanocytic and benign versus malignant nonpigmented skin tumors.
  • Among a broad spectrum of different types of vascular patterns, six main morphologies can be identified.
  • With some exceptions, comma, dotted, and linear irregular vessels are associated with melanocytic tumors, while the latter three vascular types are generally indicative of keratinocytic tumors.
  • Aside from vascular morphology, the architectural arrangement of vessels within the tumor and the presence of additional dermoscopic clues are equally important for the diagnosis.
  • This article provides a general overview of the dermoscopic evaluation of nonpigmented skin tumors and is divided into two parts.
  • Part I discusses the dermoscopic vascular patterns of benign and malignant melanocytic skin tumors.
  • Part II discusses the dermoscopic vascular patterns of benign and malignant nonmelanocytic nonpigmented skin tumors.
  • In each part, additional special management guidelines for melanocytic and nonmelanocytic nonpigmented skin tumors, respectively, will be discussed.
  • [MeSH-major] Blood Vessels / pathology. Dermoscopy / methods. Melanocytes / pathology. Skin Neoplasms / blood supply. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Education, Medical, Continuing. Female. Humans. Male. Melanoma / blood supply. Melanoma / diagnosis. Melanoma / pathology. Melanoma, Amelanotic / blood supply. Melanoma, Amelanotic / diagnosis. Melanoma, Amelanotic / pathology. Regional Blood Flow. Skin / blood supply

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20708469.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


6. Brown JA, Morgan MB: Pedunculated hemangiopericytoma-like tumor: peculiar fibroepithelial polyp or fibrous histiocytoma variant. J Cutan Pathol; 2008 Aug;35(8):748-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedunculated hemangiopericytoma-like tumor: peculiar fibroepithelial polyp or fibrous histiocytoma variant.
  • Apropos of this concern, we present a series of three cutaneous polypoid lesions that simulated fibroepithelial polyp, yet upon close scrutiny yielded histologic features of solitary fibrous tumor (SFT) or hemangiopericytoma.
  • These pedunculated lesions showed a storiform pattern of spindled cells with interspersed gaping vascular channels reminiscent of SFT or hemangiopericytoma.
  • [MeSH-major] Hemangiopericytoma / pathology. Histiocytoma, Benign Fibrous / pathology. Polyps / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422978.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.3.2.13 / Factor XIIIa
  •  go-up   go-down


7. Tardío JC: CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J Cutan Pathol; 2009 Jan;36(1):89-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions.
  • Over the past few years, a growing number of cutaneous tumors expressing CD34 is being reported.
  • The list contains benign and malignant neoplasms as well as reactive and hamartomatous lesions of diverse lineages of differentiation, including fibroblastic, myofibroblastic, fibrohistiocytic, vascular, neural, adipocytic, smooth muscle, hematopoietic, melanocytic and epithelial.
  • In part, this is because of the fact that in this area are, aside to well-defined entities, histologically and clinically diverse, recently reported cutaneous CD34-reactive lesions, whose definitions, limits and relationships are not completely established.
  • The CD34 expression plays a key role in the differential diagnosis of some tumors, such as dermatofibrosarcoma protuberans, epithelioid sarcoma or pleomorphic hyalinizing angiectatic tumor of soft parts, with important therapeutic consequences.
  • However, in all of them, the knowledge of the immunohistochemical profile contributes to our understanding of the cutaneous pathology.
  • [MeSH-major] Antigens, CD34 / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] J Cutan Pathol. 2008 Dec;35(12):1079-92 [18976402.001]
  • (PMID = 19125742.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34
  • [Number-of-references] 171
  •  go-up   go-down


8. Salomäki HH, Sainio AO, Söderström M, Pakkanen S, Laine J, Järveläinen HT: Differential expression of decorin by human malignant and benign vascular tumors. J Histochem Cytochem; 2008 Jul;56(7):639-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of decorin by human malignant and benign vascular tumors.
  • Given that angiogenesis is a sine qua non for tumor growth and progression, we attempted to examine whether human malignant vascular tumors differ from human benign vascular tumors in terms of their decorin expression and synthesis.
  • CD31 immunostaining demonstrated that the human malignant vascular tumors Kaposi's sarcoma and angiosarcoma were filled with capillary-like structures, whereas in benign cavernous and capillary hemangiomas, blood vessels were not as abundantly present.
  • By utilizing in situ hybridization and immunocytochemical assays for decorin, we showed that there was no detectable decorin mRNA expression or immunoreactivity within the tumor mass in the Kaposi's sarcoma or angiosarcoma group.
  • In contrast to sarcomas, in hemangiomas, decorin mRNA expression and immunoreactivity were observed also within the tumor mass, particularly in the connective tissue stroma surrounding the clusters of intratumoral blood vessels.
  • Finally, distribution of type I collagen was found to be similar to that of decorin in these tumor tissues.
  • Thus, decorin is likely to possess a suppressive effect on human tumor angiogenesis in vivo, as previously described by studies using different experimental models.
  • Decorin certainly provides a usable biomarker for distinguishing between benign and malignant vascular tumors in patients.
  • [MeSH-major] Extracellular Matrix Proteins / biosynthesis. Hemangioma, Capillary / metabolism. Hemangioma, Cavernous / metabolism. Hemangiosarcoma / metabolism. Proteoglycans / biosynthesis. Sarcoma, Kaposi / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Collagen Type I / metabolism. Decorin. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 May 5;275(18):13924-32 [10788518.001]
  • [Cites] J Cell Physiol. 2008 Mar;214(3):559-67 [17894407.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):345-53 [11159170.001]
  • [Cites] Microvasc Res. 2001 Jul;62(1):26-42 [11421658.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40687-92 [11546775.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3688-95 [12032837.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4765-77 [12101415.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):207-14 [12538471.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):869-78 [12937128.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):482-8 [14976536.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 24;322(3):943-9 [15336555.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):509-17 [15349825.001]
  • [Cites] Matrix. 1989;9(6):468-78 [2635760.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11389-96 [2162845.001]
  • [Cites] Exp Cell Res. 1992 Dec;203(2):395-401 [1281110.001]
  • [Cites] Eur J Cell Biol. 1992 Dec;59(2):314-21 [1493796.001]
  • [Cites] Biochem J. 1994 Sep 1;302 ( Pt 2):527-34 [8093006.001]
  • [Cites] J Invest Dermatol. 1995 Apr;104(4):509-13 [7706768.001]
  • [Cites] Acta Orthop Scand Suppl. 1995 Oct;266:61-5 [8553864.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18961-5 [8702560.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1997;32(2):141-74 [9145286.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):149-57 [9202067.001]
  • [Cites] J Clin Invest. 1998 Jan 15;101(2):406-12 [9435313.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28116-21 [9774430.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4489-92 [9988678.001]
  • [Cites] Eur J Cell Biol. 1999 Jan;78(1):44-55 [10082423.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7402-8 [10358193.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1104-10 [15690056.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):15767-72 [15701628.001]
  • [Cites] Semin Diagn Pathol. 2004 Aug;21(3):166-218 [15912727.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):27935-48 [15923192.001]
  • [Cites] Wound Repair Regen. 2006 Jul-Aug;14(4):443-52 [16939572.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1324-32 [16949929.001]
  • [Cites] Cancer Cell. 2007 Jun;11(6):539-54 [17560335.001]
  • [Cites] J Surg Oncol. 2007 Oct 1;96(5):411-8 [17579351.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • (PMID = 18413650.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / DCN protein, human; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2430166
  •  go-up   go-down


9. Chen SY, Takeuchi S, Urabe K, Hayashida S, Kido M, Tomoeda H, Uchi H, Dainichi T, Takahara M, Shibata S, Tu YT, Furue M, Moroi Y: Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. J Cutan Pathol; 2008 Aug;35(8):722-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma.
  • BACKGROUND: Activating transcription factor-2/Activator protein-1 (AP-1), Signal transducer and activator of transcription-3 and p53 are important regulators of cellular proliferation, apoptosis, differentiation in the pathogenesis of many human tumors, but the expression of phosphorylated (p)-activating transcription factor-2 (p-ATF2), phosphorylated (p)-signal transducer and activator of transcription-3 (p-STAT3) and p53 family (p63 and p73) has not been investigated in cutaneous angiosarcoma (CAS) and pyogenic granuloma (PG) so far.
  • OBJECTIVES: To investigate the expression of p-ATF2, p-STAT3 and p53 and its family in cutaneous vascular tumors (CAS and PG).
  • The p-ATF2-, p-STAT3- and p53 expression (% positive cells) in CAS and PG were significantly higher than in normal dermal vessels, but none of these transcription factors distinguished malignant (CAS)- from benign (PG) vascular tumor.
  • CONCLUSIONS: The present study suggests that overexpression of p-ATF2, p-STAT3 and possibly p53, but not p63 or p73, may contribute to the tumorigenesis of cutaneous vascular tumors.
  • [MeSH-major] Activating Transcription Factor 2 / biosynthesis. Gene Expression Regulation, Neoplastic. Granuloma, Pyogenic / metabolism. Hemangiosarcoma / metabolism. STAT3 Transcription Factor / biosynthesis. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis


10. Suresh L, Matsumura E, Calixto LE, Ruckert E, Aguirre A: Intraosseous angiomyoma of the mandible. Gen Dent; 2007 Mar-Apr;55(2):132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyoma is a benign smooth muscle tumor that usually is found in the uterus, gastrointestinal tract, or skin.
  • Microscopically, 53% of gnathic leiomyomas have a prominent vascular component that warrants a diagnosis of angiomyoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333986.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Montgomery E, Epstein JI: Anastomosing hemangioma of the genitourinary tract: a lesion mimicking angiosarcoma. Am J Surg Pathol; 2009 Sep;33(9):1364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We describe 6 cases of a poorly recognized vascular neoplasm that can simulate angiosarcoma.
  • DESIGN: Cases of a rare vascular tumor with a proclivity for the genitourinary tract encountered in our consultation material were prospectively collected between the year 1999 and 2008.
  • Vascular thrombi were typical (5/6, 83%) and the lesions had zones of central sclerosis with focal necrosis (5/6, 83%).
  • In all but one submitted consultation, the possibility of angiosarcoma had been raised based on the anastomosing vascular pattern.
  • CONCLUSIONS: Anastomosing hemangioma of the genitourinary tract is a rare neoplasm displaying some overlapping features of both sinusoidal hemangioma and hobnail hemangioma of soft tissue and skin.
  • However, in our opinion, it is a unique neoplasm with a proclivity for the kidney.
  • Its anastomosing appearance can lead to concern for angiosarcoma but, despite small numbers and limited follow-up in our series, evidence to date supports that the lesion is benign.
  • [MeSH-minor] Aged. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Factor VIII / analysis. Female. Humans. Kidney Neoplasms / chemistry. Kidney Neoplasms / pathology. Male. Middle Aged. Prospective Studies. Testicular Neoplasms / chemistry. Testicular Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606014.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / F8 protein, human; 9001-27-8 / Factor VIII
  •  go-up   go-down


12. Frikh R, Alioua Z, Harket A, Ghfir M, Sedrati O: [Glomus tumors: anatomoclinical study of 14 cases with literature review]. Ann Chir Plast Esthet; 2009 Feb;54(1):51-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glomus tumor is a neuro-myo-arterial benign hamartoma.
  • The aim of this study is to define all the unusual localizations of glomus tumor.
  • CONCLUSION: Glomus tumors are rare vascular tumors.
  • [MeSH-major] Glomus Tumor / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18938010.001).
  • [ISSN] 1768-319X
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 35
  •  go-up   go-down


13. Rizza V, Coletti G, Di Cocco P, Mazzotta C, Famulari A, Pisani F: Serious renal hemorrhage in Masson tumor. Transplant Proc; 2009 May;41(4):1402-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serious renal hemorrhage in Masson tumor.
  • Intravascular papillary endothelial hyperplasia (IPEH; Masson tumor) is a vascular lesion of blood vessels, first described in 1923 by Masson, who termed it "hemangioendotheliome vegetant Intravasculaire."
  • This lesion consists of an exuberant, usually intravascular, proliferation of normal endothelial cells and is considered to be a reactive vascular proliferation after traumatic vascular stasis.
  • The disease frequently occurs in skin and subcutaneous tissue; occurrence in solid organs is rare.
  • Intravascular papillary endothelial hyperplasia is a benign lesion but can be dangerous.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460571.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kubiena H, Mädel C, Roka J, Burjak S, Frey E, Frey M: [In-vitro suspension model of haemangioma vascular endothelial cells (HVECs)]. Handchir Mikrochir Plast Chir; 2009 Apr;41(2):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In-vitro suspension model of haemangioma vascular endothelial cells (HVECs)].
  • [Transliterated title] Hemangioma Vascular Endothelial Cells (HVECs) im In-vitro-Modell.
  • INTRODUCTION: Haemangioma is the most common tumour of infancy.
  • Its biological behaviour is one of a benign nature and characterised by a typical biphasic growth pattern.
  • In-vitro models reported so far have provided new insights in the tumour's biology and have identified possible targets for pharmacological agents.
  • PURPOSE: Our study should enhance the functionality of current in-vitro models in establishing a suspension model of isolated proliferating haemangioma vascular endothelial cells (HVECs).
  • CONCLUSIONS: Research on tumour-specific processes as well as possible pharmacological targets necessitates a stable in-vitro model of proliferating HVECs.
  • [MeSH-major] Cell Division / physiology. Endothelium, Vascular / pathology. Hemangioma / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology. Tumor Stem Cell Assay / methods

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259919.001).
  • [ISSN] 1439-3980
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


15. Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, García-Guereta L, López-Gutiérrez JC, Olivares P, Tovar J: Association of cutaneous red-to-purple hemangiomas with leptomeningeal hemangiomas. a clinical study of two patients. Neuropediatrics; 2010 Feb;41(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of cutaneous red-to-purple hemangiomas with leptomeningeal hemangiomas. a clinical study of two patients.
  • Cutaneous hemangioma is a benign vascular tumor of infancy with an initial proliferating period that appears between 1 to 2 weeks of life, extends during 18 months to 2 years of life, and then slowly regresses during several years until it disappears completely.
  • Vascular malformations are present at birth, grow commensurately with the child, and are characterized histologically by a normal rate of endothelial cell turnover, flat endothelium, thin (normal) basal membrane and normal mast cells.
  • These cutaneous anomalies are commonly associated with cerebellar malformations, main cerebral arteries anomalies, congenital cardiac anomalies and/or coarctation of the aorta and persistence of embryonic arteries.
  • Cutaneous hemangiomas can be associated with intracranial or extracranial hemangiomas that regress at the same time as the cutaneous hemangiomas.
  • Cutaneous hemangiomas may show different types of color.
  • Cutaneous red-to-purple hemangiomas are uncommon and their bright-red color is evident from the first weeks of life and remains unaltered until the hemangioma disappears.
  • Involution of the cutaneous and leptomeningeal hemangiomas seems to occur simultaneously as in other types of external and internal hemangiomas.
  • [MeSH-major] Hemangioma. Meningeal Neoplasms. Skin Diseases, Vascular. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571984.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


16. Reis RM, Reis-Filho JS, Longatto Filho A, Tomarev S, Silva P, Lopes JM: Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors. Pathol Res Pract; 2005;201(12):771-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors.
  • Here, we describe a double-immunostaining strategy for formalin-fixed, paraffin-embedded tissues that aims at evaluating the distribution of Prox-1 and CD 31 - a cytoplasmic pan-endothelial marker - in a series of 28 mucousae, cutaneous and soft tissue vascular lesions and tumors, including hemangiomas, lymphangiomas, lymphangiectasia, and Kaposi's sarcomas.
  • Our results showed that in non-lesional mucousae and skin, Prox-1 decorated exclusively the nuclei of endothelial cells in lymphatic vessels.
  • Prox-1 stained almost all the benign lymphatic vascular lesions/tumors (91%) and was absent or only focally positive in 75% of blood vascular tumors.
  • CD 31 stained endothelial cells of blood vessels of superficial and deep dermal plexuses, lymphatics, and all blood vascular lesions/tumors.
  • In conclusion, although Prox-1 expression in vascular lesions/tumors was not entirely restricted to tumors with known lymphatic differentiation, CD 31/Prox-1 double-immunolabeling can be used as an adjunct marker to identify lymphatic vessels in routinely processed formalin-fixed, paraffin-embedded samples.
  • [MeSH-major] Antigens, CD31 / metabolism. Endothelial Cells / metabolism. Homeodomain Proteins / metabolism. Mucous Membrane / metabolism. Skin / metabolism. Soft Tissue Neoplasms / metabolism. Vascular Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / analysis. Child. Child, Preschool. Female. Hemangioma / metabolism. Humans. Immunohistochemistry. Infant. Infant, Newborn. Lymphangioma / metabolism. Lymphatic Vessels / metabolism. Male. Middle Aged. Sarcoma, Kaposi / metabolism. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308102.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers; 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


17. McCluggage WG, Boyde A: Uterine angioleiomyomas: a report of 3 cases of a distinctive benign leiomyoma variant. Int J Surg Pathol; 2007 Jul;15(3):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine angioleiomyomas: a report of 3 cases of a distinctive benign leiomyoma variant.
  • We report 3 cases of a distinctive uterine leiomyoma containing numerous thick-walled vascular channels, which we term angioleiomyoma.
  • We believe angioleiomyoma should be recognized as a distinct entity and included in the World Health Organization classification of tumors of the female genital tract as a benign leiomyoma variant, similar to cellular and atypical leiomyoma.
  • Uterine angioleiomyoma has a close morphological resemblance to the similarly named skin tumor.
  • We review uterine smooth-muscle and other mesenchymal neoplasms in which prominent vascular channels are a feature.
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Adult. Antigens, Neoplasm. Calmodulin-Binding Proteins / genetics. Calmodulin-Binding Proteins / metabolism. Desmin / genetics. Desmin / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652533.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


18. Pérez-Gómez E, Eleno N, López-Novoa JM, Ramirez JR, Velasco B, Letarte M, Bernabéu C, Quintanilla M: Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene; 2005 Jun 23;24(27):4450-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of murine S-endoglin isoform and its effects on tumor development.
  • Endoglin is strongly expressed in endothelial cells, where it appears to exert a crucial role in vascular development and angiogenesis.
  • S-Eng(+) mice exhibited reduced tumor growth and neovascularization after transplantation of Lewis lung carcinoma cells.
  • In addition, S-Eng(+) mice showed a drastic inhibition of benign papilloma formation when subjected to two-stage chemical skin carcinogenesis.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806144.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / endoglin protein, mouse
  •  go-up   go-down


19. Rader C, Piorkowski J, Bass DM, Babigian A: Epulis gravidarum manum: pyogenic granuloma of the hand occurring in pregnant women. J Hand Surg Am; 2008 Feb;33(2):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pyogenic granuloma, also known as lobular capillary hemangioma, is a benign vascular tumor of the skin and mucous membranes.
  • We propose the term epulis gravidarum manum to describe this skin lesion.
  • [MeSH-major] Granuloma, Pyogenic / pathology. Hand / pathology. Pregnancy Complications / pathology. Skin Diseases / pathology


20. Trindade F, Haro R, Requena L: Giant angiolymphoid hyperplasia with eosinophilia on the chest. J Cutan Pathol; 2009 Apr;36(4):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiolymphoid hyperplasia with eosinophilia is a rare vascular proliferation characterized by single or multiple purplish, brownish papules and subcutaneous nodules, sometimes associated with pain or pruritus.
  • This rare benign process occurs with a female predominance.
  • Approximately 85% of the lesions occur in the skin of the head and neck; most of them are around the ear or on the forehead or scalp.
  • Whether angiolymphoid hyperplasia with eosinophilia represents a benign neoplasm or an unusual reaction to varied stimuli, including trauma, the etiology remains unclear.
  • The lesion is benign but may be persistent and is difficult to eradicate.
  • We report on a case of a 58-year-old Caucasian man who presented a purplish pink dome-shaped tumor of size up to 8 cm in diameter located on the chest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278439.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Gómez de la Fuente E, Sols M, Pinedo F, Alvarez-Fernández JG, Vicente FJ, Naz E, López-Estebaranz JL: [Atypical fibroxanthoma. Clinical/pathological study of 10 cases]. Actas Dermosifiliogr; 2005 Apr;96(3):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Atypical fibroxanthoma (AFX) is a rare tumor of unknown histogenesis, considered by most authorities as a superficial form of malignant fibrous histiocytoma (MFH).
  • Clinical (age, onset-diagnosis time, location, accompanying pathology, outcome), histological (architectural pattern, cell type, ulceration, vascular or perineural invasion, subcutis involvement, pleomorphism, mitosis, inflammatory infiltrate) and immunohistochemical variable were analyzed.
  • CASES REPORT: Clinical and epidemiological features coincide with those previously reported: onset late in life, short time onset-diagnosis, involvement of skin with notable sun damage and a good outcome.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476356.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


22. Abaalkhail F, Castonguay M, Driman DK, Parfitt J, Marotta P: Lobular capillary hemangioma of the liver. Hepatobiliary Pancreat Dis Int; 2009 Jun;8(3):323-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lobular capillary hemangioma (LCH) is a benign vascular tumor that is rare in adults and has never been reported in the liver.
  • This vascular lesion usually presents on the skin or mucous membranes, and predominantly affects children.
  • RESULTS: A large vascular hepatic lesion was observed in an asymptomatic 35-year-old female.
  • Large vascular hepatic lesions pose significant difficulties in discerning benign from potentially malignant conditions.
  • In this report we describe the pitfalls and radiological uncertainties with interpreting vascular lesions of the liver.

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502177.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 6
  •  go-up   go-down


23. Samaniego E, Crespo A, Sanz A: [Key diagnostic features and treatment of subungual glomus tumor]. Actas Dermosifiliogr; 2009 Dec;100(10):875-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Key diagnostic features and treatment of subungual glomus tumor].
  • [Transliterated title] Claves del diagnóstico y tratamiento del tumor glómico subungueal.
  • Glomus tumor was first described by Wood in 1812 and named as such by Masson in 1924.
  • It is a rare benign vascular tumor of the neuromyoarterial glomus.
  • The triad of cold intolerance, intense paroxysmal pain, and well-defined site of pain is characteristic of the tumor.
  • [MeSH-major] Glomus Tumor / diagnosis. Glomus Tumor / surgery. Nail Diseases / diagnosis. Nail Diseases / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038364.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Alameda JP, Moreno-Maldonado R, Navarro M, Bravo A, Ramírez A, Page A, Jorcano JL, Fernández-Aceñero MJ, Casanova ML: An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene; 2010 Dec 16;29(50):6522-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.
  • In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD(C/S)) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A.
  • In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Proliferation. Mutation. Neovascularization, Pathologic / genetics. Skin Neoplasms / blood supply. Skin Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / genetics. Cell Line, Tumor. Cell Movement / genetics. Cell Survival. Disease Progression. Humans. Mice. Mice, Nude. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838385.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


25. Xu XL, Xu CR, Chen H, Cao YH, Zeng XS, Sun JF, Guo Y: Eruptive microvenular hemangiomas in 4 Chinese patients: clinicopathologic correlation and review of the literature. Am J Dermatopathol; 2010 Dec;32(8):837-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microvenular hemangioma (MVH) is an uncommon benign vascular neoplasm that usually occurs as a solitary asymptomatic red or purple papule, nodule, or plaque with a predilection for the upper extremities.
  • [MeSH-major] Hemangioma / pathology. Skin Neoplasms / pathology. Venules / pathology
  • [MeSH-minor] Adult. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Biopsy. China. Diagnosis, Differential. Female. Herpesvirus 8, Human / genetics. Herpesvirus 8, Human / isolation & purification. Humans. Immunohistochemistry. Male. Polymerase Chain Reaction. Predictive Value of Tests. Young Adult. von Willebrand Factor / analysis

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881833.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / von Willebrand Factor
  •  go-up   go-down


26. Ibrahim M, Shwayder T: Hobnail hemangioma in a nine-year-old boy: a rare case presented with dermoscopy. Dermatol Online J; 2010;16(4):7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hobnail hemangioma is a benign vascular tumor that typically occurs on the trunk and extremities.
  • [MeSH-major] Hemangioma / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409414.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lederle W, Stark HJ, Skobe M, Fusenig NE, Mueller MM: Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am J Pathol; 2006 Nov;169(5):1767-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells.
  • Platelet-derived growth factor (PDGF) stimulates tumor growth and progression by affecting tumor and stromal cells.
  • In the HaCaT skin carcinogenesis model, transfection of immortal nontumorigenic and PDGF-receptor-negative HaCaT keratinocytes with PDGF-B induced formation of benign tumors.
  • In vivo, persistent PDGF-B expression induced enhanced tumor cell proliferation but only transiently stimulated stromal cell proliferation and angiogenesis.
  • In fibroblast cultures, long-term PDGF-BB treatment caused an initial up-regulation of vascular endothelial growth factor (VEGF)-A, followed by a drastic VEGF down-regulation and myofibroblast differentiation.
  • The PDGF-induced, persistently increased expression of the hepatocyte growth factor by fibroblasts in vitro and in vivo was most probably responsible for enhanced epithelial cell proliferation and benign tumor formation.
  • Thus, by paracrine stimulation of the stroma, PDGF-BB induced epithelial hyperproliferation, thereby promoting tumorigenicity, whereas the time-limited activation of the stroma followed by stromal maturation provides a possible explanation for the benign tumor phenotype.
  • [MeSH-minor] Actins / metabolism. Cell Proliferation / drug effects. Cell Transformation, Neoplastic. Cells, Cultured. Endostatins / metabolism. Fibroblasts / cytology. Fibroblasts / drug effects. Hepatocyte Growth Factor / pharmacology. Humans. Keratinocytes / cytology. Keratinocytes / pathology. Mesoderm / cytology. Neovascularization, Physiologic / drug effects. Paracrine Communication / drug effects. Proto-Oncogene Proteins c-sis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Time Factors. Transfection. Up-Regulation / drug effects. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1999 Jun;126(14):3047-55 [10375497.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3425-9 [3034415.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763-7 [3039506.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Science. 1988 Jun 10;240(4858):1529-31 [2836952.001]
  • [Cites] EMBO J. 1988 Dec 1;7(12):3727-35 [2463166.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):2021-5 [1848018.001]
  • [Cites] Lab Invest. 1991 Mar;64(3):321-9 [1848332.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):639-48 [1372158.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):529-34 [1434531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):393-7 [8380638.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2065-75 [8486774.001]
  • [Cites] Histochem J. 1993 Apr;25(4):251-66 [7684033.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):479-92 [9250160.001]
  • [Cites] Exp Cell Res. 1997 Aug 1;234(2):434-41 [9260914.001]
  • [Cites] Methods Mol Biol. 1997;75:305-11 [9276280.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1222-7 [9359696.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Histochem Cell Biol. 1998 Apr;109(4):349-57 [9562384.001]
  • [Cites] Exp Cell Res. 1998 Apr 10;240(1):1-6 [9570915.001]
  • [Cites] Circ Res. 1999 Feb 19;84(3):298-305 [10024303.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1294-305 [15735015.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Exp Eye Res. 2006 Jan;82(1):74-80 [16198337.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1896-902 [16322476.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):131-9 [7506710.001]
  • [Cites] J Cell Biol. 1994 May;125(4):917-28 [7514607.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):42-8 [9096664.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):398-406 [10652433.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4337-45 [10980609.001]
  • [Cites] FASEB J. 2001 Feb;15(2):447-57 [11156960.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Bioessays. 2001 Jun;23(6):494-507 [11385629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12072-7 [11593017.001]
  • [Cites] Lab Invest. 2001 Dec;81(12):1709-16 [11742041.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12456-62 [11799124.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):135-43 [12107098.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):372-83 [12453432.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):486-97 [12492491.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):533-46 [12547711.001]
  • [Cites] Lab Invest. 2003 Feb;83(2):163-73 [12594232.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] Acta Biochim Pol. 2003;50(3):647-58 [14515146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] J Cell Biol. 1982 Feb;92(2):584-8 [7061598.001]
  • [Cites] J Clin Invest. 1982 Apr;69(4):1046-9 [7076844.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • (PMID = 17071599.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Endostatins; 0 / Growth Substances; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / platelet-derived growth factor BB; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  • [Other-IDs] NLM/ PMC1780216
  •  go-up   go-down


28. Laga AC, Tajirian AL, Islam MN, Bhattacharyya I, Cohen DM, Plamondon CJ, Robinson-Bostom L: Myopericytoma: report of two cases associated with trauma. J Cutan Pathol; 2008 Sep;35(9):866-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myopericytoma is a rare, recently described tumor demonstrating a hemangiopericytoma-like vascular pattern.
  • Despite sharing morphologic features with angioleiomyoma, myofibroma and glomus tumor, myopericytoma is thought to represent a distinct perivascular myoid neoplasm of skin and soft tissues.
  • The tumor is characterized by a radial and perivascular arrangement of ovoid, spindled to round neoplastic cells that are immunoreactive to alpha-smooth muscle actin, often for h-caldesmon as well as smooth muscle myosin-heavy chain, and usually negative for desmin antibodies.
  • Most cases of myopericytoma are benign, however, local recurrence and malignancy have recently been reported, Myopericytoma can be multifocal involving a single or multiple anatomic regions, and tends to occur in dermal and superficial soft tissues of adults primarily on the extremities.
  • [MeSH-major] Hemangiopericytoma / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology. Wounds and Injuries / complications
  • [MeSH-minor] Actins / metabolism. Aged. Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Female. Humans. Male. Microfilament Proteins / metabolism. Middle Aged. Mouth Mucosa / injuries. Myosin Heavy Chains / metabolism. Nose / injuries. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18494828.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


29. Clarke LE, Lee R, Militello G, Elenitsas R, Junkins-Hopkins J: Cutaneous epithelioid hemangioendothelioma. J Cutan Pathol; 2008 Feb;35(2):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous epithelioid hemangioendothelioma.
  • Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor of endothelial cell origin.
  • We discuss the clinical and histopathologic differential diagnoses for these tumors and review additional cases in which EHE has been mistaken for benign entities clinically.
  • [MeSH-major] Diagnostic Errors. Foot Diseases / pathology. Hemangioendothelioma, Epithelioid / pathology. Skin Neoplasms / pathology


30. González-García R, Rodríguez-Campo FJ, Naval-Gías L, Sastre-Pérez J, Muñoz-Guerra MF, Usandizaga JL, Díaz-González FJ: Radial forearm free flap for reconstruction of the oral cavity: clinical experience in 55 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to evaluate our experience with the use of the RFFF for the reconstruction of oral cavity defects after tumor resection.
  • Patients were treated for benign (n = 1) and malignant (n = 54) entities.
  • All the patients underwent an abdominal split-thickness skin graft for the closure of the donor site.
  • During the immediate follow-up period, revision of the vascular anastomosis was necessary in 18.9% of the cases owing to flap ischemia.
  • [MeSH-major] Mouth / surgery. Mouth Neoplasms / surgery. Postoperative Complications. Reconstructive Surgical Procedures / methods. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197203.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Frieden IJ, Rogers M, Garzon MC: Conditions masquerading as infantile haemangioma: Part 1. Australas J Dermatol; 2009 May;50(2):77-97; quiz 98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article focuses on the myriad of diagnostic mimics of haemangiomas, including other vascular anomalies, benign growths, and malignancies.
  • [MeSH-major] Hemangioma / diagnosis. Neoplasms, Vascular Tissue / diagnosis. Skin Neoplasms / diagnosis. Vascular Malformations / diagnosis
  • [MeSH-minor] Arteriovenous Malformations / diagnosis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Glucose Transporter Type 1 / analysis. Humans. Infant. Infant, Newborn. Telangiectasis / congenital. Telangiectasis / diagnosis

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397559.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1
  • [Number-of-references] 54
  •  go-up   go-down


32. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L: Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg; 2006;59(9):961-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and eight samples were distributed in four histological groups: 30 samples from primary cutaneous melanomas, 24 from peritumoural skin sites, 28 from benign melanocytic lesions, and 26 from normal skin sites as a control.
  • RESULTS: TA was different among the four tested groups (Kruskall-Wallis test p<0.001), and increasing values of TA were observed progressing from normal skin to benign and then to malignant lesions.
  • Among melanoma samples, there was a significant association between TA and ulceration (p=0.025), TA and vascular invasion (p=0.018) and TA and mitotic rate (p=0.029) (Mann-Whitney test).
  • CONCLUSIONS: We observed that TA had increased from control skin to peritumoural skin, and then to benign melanocytic lesions and finally to melanoma, suggesting tumour progression.
  • TA showed higher values in the presence of some important histopathologic parameters related to poor prognosis in cutaneous melanoma such as ulceration, vascular invasion, satellites, high rates of mitosis, and in thicker tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Melanoma / diagnosis. Skin Neoplasms / diagnosis. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Disease Progression. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Nevus, Pigmented / diagnosis. Polymerase Chain Reaction / methods. Prognosis. Skin / enzymology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920589.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


33. Adegboyega PA, Qiu S: Hemangioma versus vascular malformation: presence of nerve bundle is a diagnostic clue for vascular malformation. Arch Pathol Lab Med; 2005 Jun;129(6):772-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangioma versus vascular malformation: presence of nerve bundle is a diagnostic clue for vascular malformation.
  • CONTEXT: Arteriovenous vascular malformations and hemangiomas are benign vascular lesions that are difficult to distinguish from one another clinically.
  • OBJECTIVE: Because it is clinically relevant to differentiate between arteriovenous vascular malformations and hemangiomas, this study was carried out to explore additional diagnostic clues that may help in the diagnosis and differentiation of these lesions.
  • DESIGN: A total of 167 cases of benign extracranial vascular lesions were retrieved from the anatomic pathology file of our institution.
  • These comprised 66 cases diagnosed as arteriovenous vascular malformations and 101 cases previously diagnosed as hemangiomas.
  • The hematoxylin-eosin-stained glass slides were reviewed, Movat pentichrome histochemical stain was used to identify elastic vessels (arteries/arterioles), and S100 immunostain was used to identify nerves within these vascular lesions.
  • RESULTS: With Movat stain, the presence of thick-walled elastic arteries was detected in 12 of the 101 cases previously diagnosed as hemangiomas, and these cases were therefore reclassified as vascular malformations.
  • Using the same criterion, 2 of the 66 cases originally diagnosed as arteriovenous vascular malformations were reclassified as hemangiomas because they lacked arterial structures.
  • Thus, with this strict criterion, we ended up with 91 cases of hemangiomas and 76 cases of arteriovenous vascular malformations.
  • Intralesional nerves were identified in 91% (69/76) of cases of arteriovenous vascular malformations, including all the 12 arteriovenous vascular malformations previously diagnosed as hemangiomas.
  • CONCLUSIONS: These results show that nerve bundles are consistently present in vascular malformations and absent in hemangiomas and so can be used as a diagnostic clue to differentiate between these lesions.
  • Also, in addition to describing a previously unreported component of vascular malformations, these data further confirm the hamartomatous nature of these lesions.
  • [MeSH-major] Arteriovenous Malformations / diagnosis. Hemangioma / diagnosis. Nerve Fibers / pathology. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Arteries / metabolism. Arteries / pathology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Elastic Tissue / pathology. Humans. Retrospective Studies. Staining and Labeling. Subcutaneous Tissue / blood supply. Subcutaneous Tissue / metabolism. Subcutaneous Tissue / pathology


34. Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ: p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene; 2008 May 15;27(22):3145-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues.
  • Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced squamous cell carcinomas, providing a model system to address mechanisms of metastasis.
  • Here, we show that benign pre-metastatic papillomas from wild-type mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels.
  • The extent of accumulation of B cells within the tumor-draining lymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential.
  • This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / physiology. Lymph Nodes / physiology. Lymphangiogenesis / genetics. Lymphatic Metastasis. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. B-Lymphocytes / pathology. Cell Proliferation. Chemotaxis, Leukocyte / genetics. Macrophages / pathology. Mice. Mice, Transgenic. Neovascularization, Pathologic / genetics. Tetradecanoylphorbol Acetate. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059331.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA68328; United States / NCI NIH HHS / CA / R01-CA99517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


35. Gleason BC, Fletcher CD: Deep "benign" fibrous histiocytoma: clinicopathologic analysis of 69 cases of a rare tumor indicating occasional metastatic potential. Am J Surg Pathol; 2008 Mar;32(3):354-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deep "benign" fibrous histiocytoma: clinicopathologic analysis of 69 cases of a rare tumor indicating occasional metastatic potential.
  • Benign fibrous histiocytoma (FH) is one of the most common mesenchymal neoplasms of the skin.
  • Several histologic variants of cutaneous FH have been described, some of which also have distinct clinical features including a propensity for local recurrence.
  • Deep benign FH is an uncommon and poorly recognized clinical subtype that arises in subcutaneous or deep soft tissue.
  • Other common findings included a hemangiopericytomalike vascular pattern (42%) and stromal hyalinization (39%).
  • Of the 37 patients for whom clinical follow-up was available (median, 40 mo), 8 (22%) had a local recurrence; in all 8 cases, the tumor had been marginally or incompletely excised.
  • The metastasizing tumors were large (6 and 9 cm) and 1 had tumor necrosis but they were otherwise histologically identical to the nonmetastasizing lesions.
  • In summary, deep FH has many histologic features in common with cutaneous cellular FH; however, it usually has a more diffusely storiform pattern than the latter, is well circumscribed, and may have striking hemangiopericytomalike vessels.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Neoplasm Metastasis / pathology. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Child. Desmin / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitosis. Necrosis. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300816.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Desmin
  •  go-up   go-down


36. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM: Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol; 2010 Mar;41(3):375-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of angiogenic molecules in benign and malignant tissues may allow identification of markers useful for prediction of sensitivity to antiangiogenic agents.
  • We hypothesized that differential expression of vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, VEGF-R2, and VEGF-R3 would be higher in melanomas than nevi and higher in advanced melanoma.
  • However, higher expression of VEGF-R3 was seen on primary lesions, potentially implicating this receptor in initiation of lymphatic tumor spread.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Cancer Res Clin Oncol. 1999 Nov;125(11):621-9 [10541969.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2823-30 [19349552.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] J Virol. 2001 Nov;75(22):10933-40 [11602733.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):325-34 [12170181.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1963-70 [12404291.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7059-65 [12460927.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):651-63 [12553370.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):4023-6 [14666713.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8 [8439321.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S19-26 [9578413.001]
  • [Cites] Clin Sci (Lond). 1998 Apr;94(4):395-404 [9640345.001]
  • [Cites] Melanoma Res. 1999 Feb;9(1):59-68 [10338335.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):770-4 [10463478.001]
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1151-61 [15610528.001]
  • [Cites] Melanoma Res. 2005 Feb;15(1):39-43 [15714119.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1089-99 [15809353.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1625-32 [16273219.001]
  • [Cites] Melanoma Res. 2005 Dec;15(6):515-22 [16314737.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Arch Dermatol Res. 2006 Feb;297(8):352-7 [16395613.001]
  • [Cites] Pathology. 2006 Apr;38(2):132-7 [16581653.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3856-63 [16778114.001]
  • [Cites] Melanoma Res. 2006 Oct;16(5):405-11 [17013089.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2519-27 [17932890.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1581-92 [18316624.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):1076-85 [19188183.001]
  • [Cites] Eur J Cancer. 2009 May;45(8):1407-14 [19157860.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2645-52 [19364969.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):577-83 [11208853.001]
  • (PMID = 20004943.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115756-04; United States / NCI NIH HHS / CA / R01 CA115756; United States / NCI NIH HHS / CA / CA115756-01; United States / NCI NIH HHS / CA / R01 CA115756-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  • [Other-IDs] NLM/ NIHMS142667; NLM/ PMC2824079
  •  go-up   go-down


37. Messeguer F, Sanmartín O, Martorell-Calatayud A, Nagore E, Requena C, Guillén-Barona C: [Acquired progressive lymphangioma (benign lymphangioendothelioma)]. Actas Dermosifiliogr; 2010 Nov;101(9):792-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired progressive lymphangioma (benign lymphangioendothelioma)].
  • [Transliterated title] Linfangioma progresivo adquirido (linfangioendotelioma benigno).
  • Acquired progressive lymphangioma is a rare vascular tumor with a locally aggressive behavior.
  • The tumor was in the hypogastric region and had arisen on a congenital vascular lesion previously diagnosed as multifocal cutaneous angiomatosis.
  • [MeSH-major] Lymphangioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Angiomatosis / congenital. Angiomatosis / pathology. Disease Progression. Edema / etiology. Humans. Male. Movement Disorders / etiology. Pain / etiology. Skin Diseases / congenital. Skin Diseases / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21034710.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Sando N, Oka K, Moriya T, Saito H, Nagakura S, Mori N, Suzuki T, Ueki H, Ohtani H: Osteosarcoma arising in the breast. APMIS; 2006 Jul-Aug;114(7-8):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were diagnosed as a fibroadenoma and a benign phyllodes tumor, respectively.
  • The tumor occupied the entire breast and measured 12x9x8.5 cm.
  • The tumor cells were spindle-shaped and pleomorphic, with large, irregular nuclei and distinct nucleoli.
  • Many tumor cells had characteristics of osteoblastic and chondroblastic elements producing osteoid, osseous, and cartilaginous intracellular substances.
  • Neoplastic cells had infiltrated the skin.
  • Tumor cells expressed vimentin, osteopontin, vascular endothelial growth factor, CD10, and alkaline phosphatase, but did not express keratin.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16907866.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


39. Tardío JC: CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J Cutan Pathol; 2008 Dec;35(12):1079-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions.
  • Over the past few years, a growing number of cutaneous tumors expressing CD34 is being reported.
  • The list contains benign and malignant neoplasms as well as reactive and hamartomatous lesions of diverse lineages of differentiation, including fibroblastic, myofibroblastic, fibrohistiocytic, vascular, neural, adipocytic, smooth muscle, hematopoietic, melanocytic and epithelial.
  • In part, this is because of the fact that in this area are, aside to well-defined entities, histologically and clinically diverse, recently reported cutaneous CD34-reactive lesions, whose definitions, limits and relationships are not completely established.
  • The CD34 expression plays a key role in the differential diagnosis of some tumors, such as dermatofibrosarcoma protuberans, epithelioid sarcoma (ES) or pleomorphic hyalinizing angiectatic tumor of soft parts, with important therapeutic consequences.
  • However, in all of them, the knowledge of the immunohistochemical profile contributes to our understanding of the cutaneous pathology.
  • [MeSH-major] Antigens, CD34 / immunology. Biomarkers, Tumor. Skin Neoplasms / immunology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Lineage. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / pathology. Diagnosis, Differential. Epidermodysplasia Verruciformis / diagnosis. Epidermodysplasia Verruciformis / pathology. Humans. Integumentary System / pathology. Sarcoma / diagnosis. Sarcoma / pathology. Skin / immunology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] J Cutan Pathol. 2009 Jan;36(1):89-102 [19125742.001]
  • (PMID = 18976402.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  • [Number-of-references] 171
  •  go-up   go-down


40. Tu YT, Tao J, Liu YQ, Li Y, Huang CZ, Zhang XB, Lin Y: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Clin Exp Dermatol; 2006 May;31(3):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.
  • BACKGROUND: Angiogenesis is the major and key factor for growth and invasion of tumours, including malignant melanoma (MM), but the factors that contribute to tumour angiogenesis are still unclear.
  • OBJECTIVE: To study expression of endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) in human MM and their relation to angiogenesis.
  • CONCLUSIONS. On the basis of the current data showing that malignant melanocytic tumours displayed strong VEGF and eNOS expression, whereas benign melanocytic proliferations showed no immunoreactivity for VEGF and eNOS, such expression may be used as a discriminating factor to distinguish malignant melanoma from pigmented naevi.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / chemistry. Nitric Oxide Synthase Type III / analysis. Skin Neoplasms / chemistry. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Endothelial Cells / pathology. Endothelium, Vascular / pathology. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Male. Middle Aged. Neovascularization, Pathologic. Nevus, Pigmented / chemistry. Nitric Oxide / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681591.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


41. Zaballos P, Puig S, Llambrich A, Malvehy J: Dermoscopy of dermatofibromas: a prospective morphological study of 412 cases. Arch Dermatol; 2008 Jan;144(1):75-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the dermoscopic features, including vascular structures and patterns associated with dermatofibromas in a large series of cases.
  • Different vascular structures were observed in 49.5% (dotted vessels in 30.6%).
  • CONCLUSION: The most common pattern associated with dermatofibroma is the classic dermoscopic pattern (pigment network and central white patch), but this tumor has a wide range of presentations.
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209171.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Zheng JW, Wang YA, Zhou GY, Zhu HG, Ye WM, Zhang ZY: [Head and neck hemangiomas: how and when to treat]. Shanghai Kou Qiang Yi Xue; 2007 Aug;16(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiomas are common benign vascular tumors of infancy characterized by a proliferative growth phase followed by very slow inevitable regression (involutive phase) between one to ten years of age, about 60% to 70% of the lesions are found in the head and neck region.
  • The argon laser (514 nm in wavelength, 0.5 mm in depth) is useful in the treatment of superficial telangiectasias and small, flat cutaneous hemangiomas.
  • Flashlamp-pumped pulsed-dye laser (FPDL, 585 nm or 595 nm in wavelength, 1.0-2.0 mm in depth) can be used in patients with cutaneous and flat hemangiomas at the sites of potential functional impairment.
  • For larger and deeper hemangiomas up to a depth of 2.0 cm, percutaneous interstitial Nd:YAG laser treatment may be preferred, because it may decrease possible cutaneous skin damage and more effectively reduce bulky, deep lesion. (5) Topical application of imiquimoid and intratumoral injection of steroids or bleomycin can be used in selected patients with rapidly growing hemangioma. (6) The indication for a primary operation is rare and limited to large hemangiomas in the eyelid or hemangiomas on the scalp.
  • A successful treatment of hemangiomas should be individualized and based on the size of the tumor, the localization, and the therapies available.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924011.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  •  go-up   go-down


43. Sobanko JF, Dagum AB, Davis IC, Kriegel DA: Soft tissue tumors of the hand. 2. Malignant. Dermatol Surg; 2007 Jul;33(7):771-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue tumors of the hand arise from skin, subcutaneous tissue, tendons, nerve, and blood vessels.
  • Their characteristics and the severity of symptoms vary markedly depending on the exact location, size, and type of tumor-and many of these tumors can have multiple forms of presentation.
  • Two articles are intended to provide an overview of benign (previous article) and malignant tumors (this article) of the hand.
  • At the completion of these review articles, participants should be able to identify and diagnose various benign and malignant hand tumors as well as understand the accepted current treatment of these growths.
  • [MeSH-minor] Aged. Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Diagnosis, Differential. Humans. Keratoacanthoma / diagnosis. Keratoacanthoma / therapy. Melanoma / diagnosis. Melanoma / therapy. Nail Diseases / diagnosis. Nail Diseases / therapy. Neurilemmoma / diagnosis. Neurilemmoma / therapy. Sarcoma / diagnosis. Sarcoma / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598842.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 212
  •  go-up   go-down


44. Requena L, Luis Díaz J, Manzarbeitia F, Carrillo R, Fernández-Herrera J, Kutzner H: Cutaneous composite hemangioendothelioma with satellitosis and lymph node metastases. J Cutan Pathol; 2008 Feb;35(2):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous composite hemangioendothelioma with satellitosis and lymph node metastases.
  • The term hemangioendothelioma has been used in recent years to name a heterogeneous group of vascular neoplasms, intermediate in both biological behavior and histopathologic appearance between benign tumors (hemangiomas) and frankly malignant tumors (angiosarcomas).
  • The latter is a vascular neoplasm showing varying combinations of benign, low-grade malignant and malignant vascular components.
  • The neoplasm showed a more aggressive behavior than other reported cases of composite hemangioendothelioma and it developed satellitosis and metastases to the inguinal lymph nodes.
  • [MeSH-major] Foot Diseases / pathology. Hemangioendothelioma / pathology. Leg / pathology. Lymphatic Metastasis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190450.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


45. Yu Y, Fuhr J, Boye E, Gyorffy S, Soker S, Atala A, Mulliken JB, Bischoff J: Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells; 2006 Jun;24(6):1605-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is a benign tumor of infancy whose hallmark is rapid growth during the first year of life followed by slow regression during early childhood.
  • The proliferating phase is characterized by abundant immature endothelial cells, the involuting phase by prominent endothelial-lined vascular channels and endothelial apoptosis, and the involuted phase by few remaining capillary-like vessels surrounded by loose fibrofatty tissue.
  • We postulated that mesenchymal stem cells (MSCs) reside in the tumor and preferentially differentiate into adipocytes.
  • The numbers of adipogenic Hem-MSCs were higher in proliferating-phase than in involuting-phase tumors and higher than in normal infantile skin.
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Cell Differentiation. Cell Proliferation. Clone Cells / pathology. Female. Granuloma, Pyogenic / genetics. Granuloma, Pyogenic / immunology. Granuloma, Pyogenic / pathology. Humans. Infant. Infant, Newborn. Neoplasm Regression, Spontaneous / pathology. Neoplastic Stem Cells / pathology. Skin Neoplasms / genetics. Skin Neoplasms / immunology. Skin Neoplasms / pathology. X Chromosome Inactivation

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456130.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR 048564
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


46. Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA: Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer; 2008;8:362
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.
  • BACKGROUND: Tumor necrosis and apoptotic activity are considered important in cancer progression, but these features have not been much studied in melanomas.
  • Our hypothesis was that rapid growth in cutaneous melanomas of the vertical growth phase might lead to tissue hypoxia, alterations in apoptotic activity and tumor necrosis.
  • We proposed that these tumor characteristics might be associated with changes in expression of cell adhesion proteins leading to increased invasive capacity and reduced patient survival.
  • METHODS: A well characterized series of nodular melanoma (originally 202 cases) and other benign and malignant melanocytic tumors (109 cases) were examined for the presence of necrosis, apoptotic activity (TUNEL assay), immunohistochemical expression of hypoxia markers (HIF-1 alpha, CAIX, TNF-alpha, Apaf-1) and cell adhesion proteins (alphavbeta3 integrin, CD44/HCAM and osteopontin).
  • We hypothesized that tumor hypoxia and necrosis might be associated with increased invasiveness in melanoma through alterations of tumor cell adhesion proteins.
  • RESULTS: Necrosis was present in 29% of nodular melanomas and was associated with increased tumor thickness, tumor ulceration, vascular invasion, higher tumor proliferation and apoptotic index, increased expression of alphavbeta3 integrin and poor patient outcome by multivariate analysis.
  • Tumor cell apoptosis did also correlate with reduced patient survival.
  • Expression of TNF-alpha and Apaf-1 was significantly associated with tumor thickness, and osteopontin expression correlated with increased tumor cell proliferation (Ki-67).
  • CONCLUSION: Tumor necrosis and apoptotic activity are important features of melanoma progression and prognosis, at least partly through alterations in cell adhesion molecules such as increased alphavbeta3 integrin expression, revealing potentially important targets for new therapeutic approaches to be further explored.
  • [MeSH-major] Integrin alphaVbeta3 / metabolism. Melanoma / metabolism. Melanoma / pathology. Necrosis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD44 / metabolism. Apoptosis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Gene Expression Regulation, Neoplastic. Humans. In Situ Nick-End Labeling. Kaplan-Meier Estimate. Multivariate Analysis. Osteopontin / metabolism. Prognosis. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2004 Feb;14(1):29-37 [15091191.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1845-53 [10815907.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):61-70 [15305376.001]
  • [Cites] J Bone Miner Res. 2004 Oct;19(10):1706-11 [15355566.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):716-23 [10925366.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Eur J Cell Biol. 2000 Jul;79(7):502-12 [10961450.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):957-65 [10980134.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1415-30 [11073801.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1009-19 [11891198.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):387-96 [11950912.001]
  • [Cites] Cytopathology. 2002 Feb;13(1):11-21 [11985564.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):854-61 [12095550.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):156-67 [12209993.001]
  • [Cites] Connect Tissue Res. 2002;43(2-3):308-19 [12489175.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65 [12496470.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):17-22 [12559172.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Exp Dermatol. 2004 Feb;13(2):93-7 [15009102.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1089-95 [15305193.001]
  • [Cites] Cancer Res. 1969 Mar;29(3):705-27 [5773814.001]
  • [Cites] Ann Surg. 1970 Nov;172(5):902-8 [5477666.001]
  • [Cites] Adv Immunol. 1993;54:271-335 [8379464.001]
  • [Cites] J Clin Pathol. 1995 Mar;48(3):242-4 [7730486.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):169-73 [8661192.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):926-30 [9291817.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):535-9 [9355977.001]
  • [Cites] J Cutan Pathol. 1998 Apr;25(4):199-203 [9609138.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Br J Dermatol. 1998 May;138(5):763-8 [9666819.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1435-42 [9811334.001]
  • [Cites] Hum Pathol. 1999 May;30(5):562-7 [10333228.001]
  • [Cites] Int J Oncol. 1999 Sep;15(3):595-9 [10427146.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2387-96 [15781654.001]
  • [Cites] Mol Biol Cell. 2005 Apr;16(4):1901-12 [15689487.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2583-90 [15814637.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):1044-52 [15854047.001]
  • [Cites] Int J Cancer. 2005 Sep 20;116(5):734-9 [15849727.001]
  • [Cites] Exp Dermatol. 2005 Nov;14(11):811-8 [16232302.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14 [16361544.001]
  • [Cites] Pigment Cell Res. 2006 Feb;19(1):43-50 [16420245.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):225-39 [17440684.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):144-50 [18023025.001]
  • [Cites] J Cell Sci. 2000 May;113 ( Pt 9):1535-42 [10751145.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):43-50 [15185341.001]
  • (PMID = 19061491.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Integrin alphaVbeta3; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2631589
  •  go-up   go-down


47. Pisacane AM, Risio M: VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res; 2005 Feb;15(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
  • Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2) play a key role in vasculogenesis and angiogenic sprouting, which are crucial for tumour development and metastasis.
  • In order to determine their possible role in the acquisition of metastatic potential throughout melanocytic tumour progression, VEGF and VEGFR-2 immunohistochemical expression were evaluated in 36 human melanocytic tumours of the skin (24 malignant melanomas and 12 common naevi).
  • Taken together, these data indicate that VEGF production is a common event in benign melanocytic tumours, whereas VEGFR-2 expression, co-localized in the cytoplasmic and nuclear membrane, is associated with progression towards invasive melanoma.
  • The role exerted by VEGF/VEGFR-2, however, seems to be independent of the development of a tumour-related capillary network.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Melanoma / metabolism. Nevus, Pigmented / metabolism. Skin Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Cell Nucleus / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714119.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


48. Salazard B, Philandrianos C: [Children's tumors of the hand]. Chir Main; 2008 Dec;27 Suppl 1:S185-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is the most common soft-tissue tumor in infancy and childhood.
  • Other vascular abnormalities are capillary malformation, venous malformation.
  • Many other benign soft-tissue and cutaneous tumors can be seen (ganglion cyst, naevus, fibroma...).
  • [MeSH-major] Bone Neoplasms. Fibroma. Hand. Nevus. Skin Neoplasms
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Female. Hamartoma / congenital. Hamartoma / diagnosis. Humans. Infant. Infant, Newborn. Male. Neoplasms, Vascular Tissue / diagnosis. Neoplasms, Vascular Tissue / epidemiology. Nevus, Pigmented / diagnosis. Nevus, Pigmented / epidemiology. Nevus, Pigmented / surgery. Skin Transplantation


49. Capelle X, Syrios P, Chantraine F, Rigo V, Schaaps JP, Kridelka F, Foidart JM: [A rare case of placental chorioangioma associated with neonatal disseminated hemangiomatosis]. J Gynecol Obstet Biol Reprod (Paris); 2009 May;38(3):246-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Placental chorioangioma is a benign vascular tumor.
  • [MeSH-major] Hemangioma / diagnosis. Liver Neoplasms / diagnosis. Placenta Diseases / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303223.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


50. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • It is secreted by all vascular cells and plays a role in tumor invasion and metastasis, presumably by plasmin-mediated matrix remodeling.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Restoration of TFPI-2 led to decreased invasiveness of transfected cells compared to parental and vector controls in Matrigel and spheroid assays and inhibition of angiogenesis in in vitro co-cultures with human umbilical vein endothelial cells (HUVEC) and in vivo dorsal skin assay studies.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


51. Paik AS, Lee PH, O'Grady TC: Acquired progressive lymphangioma in an HIV-positive patient. J Cutan Pathol; 2007 Nov;34(11):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired progressive lymphangioma (APL) is a rare condition characterized by benign proliferation of thin-walled vessels lined by flattened endothelial cells.(1-4) Although benign, the acquired nature of this tumor may lead to misdiagnosis as a malignant vascular tumor.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphangioma / complications. Lymphangioma / pathology. Skin Neoplasms / complications. Skin Neoplasms / pathology


52. Stojsic Z, Brasanac D, Kokai G, Vujovic D, Zivanovic D, Boricic I, Bacetic D: Intestinal intussusception due to a pyogenic granuloma. Turk J Pediatr; 2008 Nov-Dec;50(6):600-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pyogenic granuloma (PG), also known as lobular capillary hemangioma, is a benign vascular tumor, most commonly arising on the skin and the oral mucosa.

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227429.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


53. Hoekzema R, Zonneveld IM, van der Wal AC: Type 2 segmental glomangiomas. Dermatol Online J; 2010;16(1):8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glomangiomas of the skin, currently named glomuvenous malformations (GVMs), are benign vascular lesions composed of thin-walled distorted blood vessels, surrounded by variable rows of glomus cells.
  • As several satellite lesions emerged at distant skin sites later in life, our case probably represents type 2 segmental GVMs, caused by localized loss of heterozygosity in an individual carrying a heterozygous germline mutation in the glomulin gene.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Glomus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137750.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GLMN protein, human
  •  go-up   go-down


54. Browning J, Frieden I, Baselga E, Wagner A, Metry D: Congenital, self-regressing tufted angioma. Arch Dermatol; 2006 Jun;142(6):749-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tufted angioma (known in Japanese literature as angioblastoma of Nakagawa) is an uncommon, histologically benign, vascular tumor.
  • [MeSH-major] Hemangioma, Capillary / diagnosis. Neoplasm Regression, Spontaneous / pathology. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Angioma.
  • Genetic Alliance. consumer health - Tufted angioma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785378.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Plaza JA, Morrison C, Magro CM: Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates. J Cutan Pathol; 2008 Apr;35(4):358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates.
  • While some unequivocally benign infiltrates are easy to distinguish from cutaneous T-cell lymphoma (CTCL), drug-associated lymphomatoid hypersensitivity reaction and cutaneous lesions of collagen vascular disease can show cytologic atypia, clonality and an immunophenotypic profile that closely simulates CTCL and cause diagnostics difficulties.
  • Similar immunophenotypic and molecular abnormalities to those of malignant lymphoma can also be observed in pityriasis lichenoides chronica (PLC), large plaque parapsoriasis (LPP), pigmented purpuric dermatosis (PPD) and atypical lymphocytic lobular panniculitis leading one to consider these entities as forms of cutaneous lymphoid dyscrasia.
  • The purpose of our study was to evaluate the distinction of these various subcategories of cutaneous T-cell infiltrates by assessment of T-cell receptor (TCR)-beta gene rearrangement.
  • Formalin-fixed paraffin-embedded skin biopsies from 80 patients containing a T-cell dominant lymphocytic infiltrate were analyzed for TCR-beta gene rearrangement.
  • However, some cases of drug associated lymphomatoid hypersensitivity, collagen vascular disease and the various cutaneous lymphoid dyscrasias (i.e.
  • [MeSH-major] Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Genes, T-Cell Receptor / genetics. Leukemic Infiltration. Lymphoma, T-Cell, Cutaneous / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Clone Cells. Humans. Lymphocytes / pathology. Panniculitis / genetics. Panniculitis / metabolism. Panniculitis / pathology. Parapsoriasis / genetics. Parapsoriasis / metabolism. Parapsoriasis / pathology. Pigmentation Disorders. Pityriasis Lichenoides / genetics. Pityriasis Lichenoides / metabolism. Pityriasis Lichenoides / pathology. Purpura / genetics. Purpura / metabolism. Purpura / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976210.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Avilés-Izquierdo JA, Velázquez-Tarjuelo D, Lecona-Echevarría M, Lázaro-Ochaita P: [Dermoscopic features of eccrine poroma]. Actas Dermosifiliogr; 2009 Mar;100(2):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eccrine poroma is a benign adnexal neoplasm that clinically may mimic malignant skin tumors such as squamous cell carcinoma and amelanotic melanoma.
  • The lesions were characterized by multiple red lacunes and a polymorphous vascular pattern in both cases.
  • Dermoscopy can improve the clinical diagnosis of this benign adnexal skin tumor.
  • [MeSH-minor] Aged. Aged, 80 and over. Buttocks. Diagnosis, Differential. Female. Humans. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445878.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Káram-Orantes M, Fonte-Avalos V, Zuloaga-Salcedo S, Domínguez-Cherit J: [Frequency of benign tumors at the Hospital General "Dr. Manuel Gea Gonzalez". Record review between 2000-2006]. Gac Med Mex; 2007 Sep-Oct;143(5):371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frequency of benign tumors at the Hospital General "Dr. Manuel Gea Gonzalez". Record review between 2000-2006].
  • BACKGROUND: Benign skin neoplasms are defined as autonomous growing tissue unrelated to normal growing of the skin, that persist even after the originating stimulus dissapears.
  • Almost all human beings have a certain number of benign cutaneous neoplasms and many never seek medical attention.
  • The aim of this study was to record the number of benign tumors studied at the Dermatology Department of a medical facility.
  • We included year of admission, number of biopsies, sex, age, tumor location, histological and clinical diagnoses.
  • RESULTS: We analyzed 9,436 biopsies of which 3,765 constituted benign neoplasms; 595 were not included and our total sample was 3,170 tumors.
  • The most frequent tumors according to histopathological diagnoses in descending order were: melanocytic, cutaneous cysts, fibrous tumors, vascular tumors, epidermal tumors, fat tumors, tumors with hair differentiation, neural tumors, glandular tumors, tumors with sebaceous differentiation, cartilage and bone tumors, and smooth muscle tumors.
  • The most common benign tumors were: Melanocytic nevi, epidermal cysts, seborrheic keratoses, pyogenic granulomas, lipomas and dermatofibromas.
  • CONCLUSIONS: Melanocytes represented by melanocytic nevi (junctional, intradermic and compound) were the most frequent benign neoplasms, followed by epidermoid cysts.
  • Our results illustrate the most common benign tumors observed in a dermatology department.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246930.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


58. Hansen SL, Dosanjh A, Young DM, Boudreau N, Hoffman WY: Hemangiomas and homeobox gene expression. J Craniofac Surg; 2006 Jul;17(4):767-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiomas are the most common benign tumor of childhood.
  • Improved understanding of angiogenesis over the last two decades is helping to delineate differences between various vascular tumors.
  • Homeobox (Hox) genes are master transcription factors, which have a centrol role during organogenesis, and more recently have been documented to be involved in postnatal tissue remodeling and tumor angiogenesis.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Genes, Homeobox / genetics. Hemangioma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877932.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / F32GM2084901; United States / PHS HHS / / K0-8 G00674; United States / NIGMS NIH HHS / GM / P50GM27345
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Transcription Factors; 127609-92-1 / HOXA4 protein, human
  •  go-up   go-down


59. Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG: A series of 146 peripheral non-neural sheath nerve tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg; 2005 Feb;102(2):256-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: This is a retrospective review of 146 surgically treated benign and malignant peripheral non-neural sheath tumors (PNNSTs).
  • Tumor classifications with patient numbers, locations of benign PNNSTs, and surgical techniques and adjunctive treatments are presented.
  • The results of a literature review regarding tumor frequencies are presented.
  • METHODS: One hundred forty-six patients with 111 benign and 35 malignant PNNSTs were treated between 1969 and 1999 at the Louisiana State University Health Sciences Center (LSUHSC).
  • The benign tumors included 33 ganglion cysts, 16 cases of localized hypertrophic neuropathy, 12 lipomas, 12 tumors of vascular origin, and 11 desmoid tumors.
  • The locations of benign PNNSTs were the following: 33 in the brachial plexus region, 39 in an upper extremity, one in the pelvic plexus, and 38 in a lower extremity.
  • There were two melanomas metastatic to nerve and one tumor each that had metastasized from the bladder, rectum, skin, head and neck, and thyroid, and from a primary Ewing sarcoma.
  • CONCLUSIONS: There were more benign PNNSTs than malignant ones.
  • Benign tumors were relatively equally distributed in the brachial plexus region and upper and lower extremities, with the exception of the pelvic plexus, which had only one tumor.

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739553.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Osio A, Fraitag S, Hadj-Rabia S, Bodemer C, de Prost Y, Hamel-Teillac D: Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol; 2010 Jul;146(7):758-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tufted angioma (TA) is a rare benign vascular tumor that mostly appears during infancy or early childhood.
  • Presentation was a nascent or florid tumor, usually a dusky red to violaceous plaque, that was indurated, firm, and sometimes associated with hyperhidrosis or hypertrichosis.
  • [MeSH-major] Hemangioma / pathology. Skin / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644037.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Murali R, Palfreeman S: Clear cell atypical fibroxanthoma - report of a case with review of the literature. J Cutan Pathol; 2006 May;33(5):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell atypical fibroxanthoma (CCAFX) is a rare variant of atypical fibroxanthoma (AFX), a pleomorphic dermal tumour associated with a good prognosis.
  • Sections showed an ulcerated nodule composed of pleomorphic spindled and polygonal cells with clear cytoplasm, invested by a delicate vascular stroma, reminiscent of clear cell renal cell carcinoma.
  • The tumour cells stained with vimentin, CD68 and CD99 and were cytokeratin-negative.
  • The diagnosis of CCAFX requires the exclusion of other pleomorphic clear cell tumours that can occur in the skin by using a combination of morphology, immunohistochemistry and electronmicroscopy.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Ear / pathology. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640540.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Grasso M, Blanco S, Raber M, Nespoli L: Elasto-sonography of the testis: preliminary experience. Arch Ital Urol Androl; 2010 Sep;82(3):160-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lesion size was defined by the major diameter The color Doppler examination was performed to evaluate the vascular pattern.
  • To obtain images that were appropriate for analysis, we applied the probe with only light pressure, which we defined as a level of pressure that maintained contact with the skin and permitted imaging conditions for which the association between pressure and strain was essentially proportional.
  • In the remaining 3 cases it allowed a better characterization of 2 small benign tumors and of an intratesticular haematoma.
  • Infact elastosonography resulted helpful in the determination of 2 small lesions diagnosticated after surgery as Sertoli tumor and adenomatoid tumor of the testis, respectively in a third case the elastosonography identified an intraparenchimal hematoma (confirmed after surgical exploration )in the differential diagnosis with a solid tumor.

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121434.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Aykut K, Ozdemir C, Acikel U: Infected giant lymphangioma circumscriptum treated with a combination therapy. Ann Vasc Surg; 2010 Oct;24(7):953.e11-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma circumscriptum is an uncommon benign disorder of skin and subcutaneous tissues characterized by dilated lymphatic channels.
  • It is an uncommon vascular tumor and it rarely becomes infected.
  • We report a 20-year-old man who had an infected giant tumor in his left thigh.

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AMPICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20599349.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 65DT0ML581 / sultamicillin; 7C782967RD / Ampicillin; S4TF6I2330 / Sulbactam
  •  go-up   go-down


64. Lucas DR: Angiosarcoma, radiation-associated angiosarcoma, and atypical vascular lesion. Arch Pathol Lab Med; 2009 Nov;133(11):1804-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma, radiation-associated angiosarcoma, and atypical vascular lesion.
  • Most are sporadic, presenting as cutaneous tumors in the scalp/face of elderly patients.
  • Radiation-associated angiosarcoma typically presents as a cutaneous tumor several years posttherapy.
  • Atypical vascular lesion refers to a small, usually lymphatic-type vascular proliferation in radiated skin.
  • Although most atypical vascular lesions pursue a benign course, they recur and very rarely progress to angiosarcoma.
  • Distinguishing this lesion from well-differentiated angiosarcoma in a biopsy can be challenging, especially because areas indistinguishable from atypical vascular lesion are found adjacent to angiosarcoma.
  • Recently, vascular-type atypical vascular lesion, which resembles hemangioma, has been described, thus expanding the definition of this entity.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / pathology. Vascular Diseases / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Breast Neoplasms / radiotherapy. Female. Humans. Skin / blood supply

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886715.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 12
  •  go-up   go-down


65. Lee IJ, Yoo YM, Lim H, Park MC: Glomus tumor of the back: a rare location. J Craniofac Surg; 2009 Nov;20(6):2153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the back: a rare location.
  • A subsequent diagnostic evaluation revealed the presence of a glomus tumor.
  • Glomus tumors are rare, benign, small vascular tumors, which originate from glomus bodies present in the reticular dermis.
  • Nevertheless, to the best of our knowledge, this glomus tumor that occurred on the back is very rare.
  • [MeSH-major] Back / pathology. Glomus Tumor / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884843.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Blum A, Metzler G, Bauer J: Polymorphous vascular patterns in dermoscopy as a sign of malignant skin tumors. A case of an amelanotic melanoma and a porocarcinoma. Dermatology; 2005;210(1):58-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous vascular patterns in dermoscopy as a sign of malignant skin tumors. A case of an amelanotic melanoma and a porocarcinoma.
  • BACKGROUND: Using dermoscopy (dermatoscopy, epiluminescence microscopy), malignant skin tumors can be detected earlier and unnecessary excisions of benign tumors can be avoided.
  • OBJECTIVE: Description of the dermoscopic vascular patterns of an amelanotic melanoma and a porocarcinoma.
  • RESULTS: On dermoscopy polymorphous vascular patterns with pinpoint and hairpin-like vessels were seen.
  • CONCLUSION: A reddish tumor without any pigmented network, globules or streaks but with polymorphous vascular patterns must be considered a malignant melanocytic or nonmelanocytic skin tumor.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604548.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Kontogianni-Katsaros K, Kairi-Vassilatoy E, Grapsa D, Papadias K, Hasiakos D, Kondi-Pafitis A: Angiokeratoma of the vulva: a rare benign vascular tumor mimicking malignancy--case reports. Eur J Gynaecol Oncol; 2006;27(6):632-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiokeratoma of the vulva: a rare benign vascular tumor mimicking malignancy--case reports.
  • Angiokeratomas are rare benign dermal lesions of the external genital system and occur before the age of 50 years.
  • [MeSH-major] Angiokeratoma / pathology. Skin Neoplasms / pathology. Vulvar Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290602.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


68. Sun ZJ, Cai Y, Zhao YF, Hu X, Zhang W, Chen XM, Lai FM: Epithelioid angiomatous nodule of head and neck. Pathol Res Pract; 2009;205(11):753-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid vascular proliferations comprise a wide morphologic spectrum, ranging from reactive hyperplasia via benign tumor to malignant conditions.
  • Epithelioid angiomatous nodule (EAN) is a recently recognized benign vascular proliferation with distinct clinical and pathological features.
  • The sites of origin included the tongue (n=2), skin of the lip (n=2), periorbital and temporal skin (n=1), and nose (n=1).
  • The distinction of EAN from other lesions of the heterogeneous group with epithelioid vascular proliferation can usually be made on the basis of the clinical and morphological features.
  • [MeSH-major] Angiomatosis / diagnosis. Head and Neck Neoplasms / diagnosis. Hemangioendothelioma, Epithelioid / diagnosis. Hemangioma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596525.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


69. Luzar B, Calonje E: Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol; 2010 Mar;37(3):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Histological features analyzed in 66 AFXs were: ulceration, morphological variants, growth pattern, location in the skin and vascular/perineural invasion.
  • All developed on sun damaged skin.
  • No vascular/perineural invasion was seen.
  • This study expands the spectrum of non-vascular CD31 positive tumors.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Arm / pathology. Biomarkers, Tumor. Diagnosis, Differential. Female. Fibrosis / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Scalp / pathology. Sex Factors


70. Makino E, Yamada J, Tada J, Arata J, Iwatsuki K: Cutaneous angiolipoleiomyoma. J Am Acad Dermatol; 2006 Jan;54(1):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous angiolipoleiomyoma.
  • We describe a girl with cutaneous angiolipoleiomyoma on the buttock.
  • The 16-year-old girl had a 2.5- x 1.5-cm subcutaneous tumor on the right buttock, which was slightly tender.
  • The tumor appeared to be vascular and was, therefore, surgically excised.
  • Cutaneous angiomyolipoma, which is also known as cutaneous angiolipoleiomyoma, is a rare benign mesenchymal tumor.
  • We point out the differences between the cutaneous and renal forms of angiomyolipoma, and conclude that the cutaneous lesion is distinct from a renal lesion in several aspects, including tuberous sclerosis complex association and immunoreactivity to both HMB-45 and MART-1.
  • [MeSH-major] Angiomyolipoma / diagnosis. Buttocks. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16384779.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kreusel KM: Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam Cancer; 2005;4(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Capillary retinal angioma, a benign vascular tumor, is the classical ocular lesion in VHL.
  • Extension of the tumor beyond the chiasm worsens the prognosis quoad vitam.
  • The hallmark of NF 1, namely cutaneous neurofibroma can cause visual impairment when affecting the skin of the eyelids.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmic Paediatr Genet. 1991 Mar;12(1):11-7 [1908964.001]
  • [Cites] Am J Ophthalmol. 1980 Apr;89(4):540-5 [7369317.001]
  • [Cites] Arch Ophthalmol. 1991 May;109(5):662-6 [1902661.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):63-6 [8021787.001]
  • [Cites] J Pediatr. 1989 May;114(5):788-92 [2497236.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1790-7 [7425905.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):167-83 [8832460.001]
  • [Cites] Eye (Lond). 1996;10 ( Pt 6):758-9 [9091382.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2003 Sep-Oct;40(5):293-6 [14560838.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Jun;81(3):309-10 [12780414.001]
  • [Cites] Trans Am Ophthalmol Soc. 1970;68:367-424 [5535648.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2000 Nov;238(11):916-21 [11148816.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51 [12403562.001]
  • [Cites] Ophthalmology. 1981 Apr;88(4):348-54 [6789269.001]
  • [Cites] Pediatr Neurosurg. 2002 Sep;37(3):122-36 [12187057.001]
  • [Cites] Arch Ophthalmol. 1974 Aug;92(2):121-5 [4858803.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2240-8 [11097604.001]
  • [Cites] Q J Med. 1990 Nov;77(283):1151-63 [2274658.001]
  • [Cites] Ophthalmic Surg. 1988 Oct;19(10):743-7 [3194109.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):555-61 [9681858.001]
  • [Cites] Eur J Med Res. 2000 Feb 28;5(2):47-58 [10720563.001]
  • [Cites] Eye (Lond). 1993;7 ( Pt 1):95-101 [8325432.001]
  • [Cites] Ophthalmology. 1996 Feb;103(2):329-35 ; discussion 334-5 [8594522.001]
  • [Cites] Childs Nerv Syst. 1994 Sep;10(7):426-9 [7842431.001]
  • [Cites] Arch Ophthalmol. 1995 Sep;113(9):1163-7 [7661750.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1996 Jul-Aug;33(4):255-9 [8827563.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):48-54 [10647718.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):949-52 [12820328.001]
  • [Cites] Int Ophthalmol Clin. 1997 Fall;37(4):159-70 [9429939.001]
  • [Cites] Ophthalmology. 1982 Nov;89(11):1213-9 [6818504.001]
  • [Cites] Ophthalmology. 1984 Aug;91(8):929-35 [6436764.001]
  • [Cites] Br J Ophthalmol. 1987 Mar;71(3):235-8 [3103673.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Lancet. 1991 May 4;337(8749):1052-4 [1673491.001]
  • [Cites] Plast Reconstr Surg. 1993 Jul;92(1):1-11 [8516385.001]
  • [Cites] Eur J Pediatr. 1991 Oct;150(12):835-8 [1743214.001]
  • [Cites] Can J Neurol Sci. 2002 May;29(2):132-8 [12035834.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):1-29 [2642584.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):45-52 [2104571.001]
  • [Cites] Surv Ophthalmol. 1994 Mar-Apr;38(5):427-52 [8009427.001]
  • [Cites] Am J Ophthalmol. 1978 Nov;86(5):684-7 [102202.001]
  • [Cites] Arch Pathol Lab Med. 1984 Feb;108(2):160-3 [6421263.001]
  • [Cites] Arch Intern Med. 1976 Jul;136(7):769-77 [945722.001]
  • [Cites] Am J Ophthalmol. 2000 Jul;130(1):117-9 [11004270.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1996 Dec;12(4):245-59 [8944385.001]
  • [Cites] Ophthalmology. 1999 Mar;106(3):623-9 [10080225.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1386-92 [9709747.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):768-72 [8970601.001]
  • [Cites] Am J Dis Child. 1980 Feb;134(2):182-3 [6766271.001]
  • [Cites] Neurologia. 1994 May;9(5):173-7 [8024821.001]
  • [Cites] Can J Ophthalmol. 1986 Dec;21(7):276-83 [3801976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):615-23 [1907959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):927-32 [2323979.001]
  • [Cites] Eur J Ophthalmol. 2002 Sep-Oct;12(5):413-8 [12474925.001]
  • [Cites] Q J Med. 1988 Mar;66(251):233-49 [3200963.001]
  • [Cites] J Child Neurol. 2003 Jul;18(7):504-8 [12940659.001]
  • [Cites] Arch Ophthalmol. 1999 Mar;117(3):371-8 [10088816.001]
  • [Cites] Am J Ophthalmol. 1976 Aug;82(2):193-204 [986118.001]
  • (PMID = 15883709.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 63
  •  go-up   go-down


72. Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F: S100A13 is a new angiogenic marker in human melanoma. Mod Pathol; 2010 Jun;23(6):804-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is critical in melanoma progression and metastasis and relies on the synthesis and release of proangiogenic molecules such as vascular endothelial growth factor (VEGF)-A and fibroblast growth factors (FGFs).
  • S100A13 is upregulated in astrocytic gliomas, in which it correlates with VEGF-A expression, microvessel density and tumor grading, and promotes a more aggressive, invasive phenotype in lung cancer-derived cell lines.
  • To investigate the involvement of S100A13 in human cutaneous melanoma, we analyzed a series of 87 cutaneous melanocytic lesions: 14 common acquired melanocytic nevi, 14 atypical, so-called 'dysplastic' nevi, 45 melanomas (17 radial growth phase and 28 vertical growth phase) and 14 melanoma metastases.
  • We found that S100A13 was expressed in melanocytic lesions; compared with benign nevi, S100A13 protein expression was significantly upregulated in melanomas (P=0.024), in which it correlated positively with the intensity of VEGF-A staining (P=0.041) and microvessel density (P=0.007).
  • In conclusion, S100A13 is expressed in melanocytic lesions when the angiogenic switch occurs and it may cooperate with VEGF-A in supporting the formation of new blood vessels, favoring the shift from radial to vertical tumor growth.
  • [MeSH-major] Biomarkers, Tumor / analysis. Capillaries / chemistry. Melanoma / blood supply. Melanoma / chemistry. Neovascularization, Pathologic / metabolism. S100 Proteins / analysis. Skin Neoplasms / blood supply. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Antigens, CD / analysis. Female. Fibroblast Growth Factor 1 / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. Receptors, Cell Surface / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94 [10838264.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6199-206 [19917835.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22544-52 [11410600.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1826-31 [11919240.001]
  • [Cites] FASEB J. 2003 Jun;17(9):984-92 [12773481.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):990-7 [15133476.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Reprod Domest Anim. 2004 Oct;39(5):321-7 [15367264.001]
  • [Cites] Semin Oncol. 1975 Jun;2(2):119-47 [1234372.001]
  • [Cites] Science. 1984 Aug 31;225(4665):932-5 [6382607.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):99-104 [7686347.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6061-6 [8261423.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):329-36 [8311116.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29039-42 [7493920.001]
  • [Cites] J Invest Dermatol. 1996 Feb;106(2):207-8 [8601716.001]
  • [Cites] Melanoma Res. 1996 Apr;6(2):133-7 [8791271.001]
  • [Cites] Melanoma Res. 1996 Jun;6(3):223-30 [8819125.001]
  • [Cites] J Cutan Pathol. 1997 Apr;24(4):212-8 [9138111.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):599-623 [9210357.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):70-4 [10030417.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):770-4 [10463478.001]
  • [Cites] Reprod Biol. 2005 Mar;5(1):51-67 [15821778.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1955-8 [15900299.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4993-7 [15958538.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):87-101 [16165218.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):201-14 [16683912.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):251-9 [16773219.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):555-65 [18083379.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):151-9 [18061437.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):357-64 [17566693.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1327-43 [17786931.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Neoplasma. 2008;55(4):273-9 [18505336.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):67-74 [18400376.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):21-30 [18660796.001]
  • [Cites] Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13 [19617299.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1717-26 [11245488.001]
  • (PMID = 20208480.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / S100 Proteins; 0 / S100A13 protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 104781-85-3 / Fibroblast Growth Factor 1
  • [Other-IDs] NLM/ NIHMS204422; NLM/ PMC2882157
  •  go-up   go-down


73. Onuma K, Sato Y, Ogawara S, Shirasawa N, Kobayashi M, Yoshitake J, Yoshimura T, Iigo M, Fujii J, Okada F: Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol; 2009 Nov;175(5):2171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.
  • These results indicate that nano-sized TiO(2) has the potential to convert benign tumor cells into malignant ones through the generation of ROS in the target cells.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Fibrosarcoma. Nanoparticles / chemistry. Neoplasm Invasiveness. Titanium / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytokines / genetics. Cytokines / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Dinoprostone / metabolism. Female. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Inbred C57BL. Particle Size. Reactive Oxygen Species / metabolism. Thymosin / genetics. Thymosin / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Med. 1988 Dec;30(12):937-42 [3230444.001]
  • [Cites] J Toxicol Environ Health. 1990;29(4):417-29 [2325155.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(6):358-64 [2386981.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5512-20 [8955201.001]
  • [Cites] J Biochem. 1997 Aug;122(2):459-66 [9378727.001]
  • [Cites] Br Med Bull. 1997;53(3):662-8 [9374044.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):87-90 [9414101.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):85-100 [9457471.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):L81-6 [9458804.001]
  • [Cites] J Appl Toxicol. 1998 Sep-Oct;18(5):307-12 [9804429.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 1999 Sep-Oct;12(5):247-56 [10461093.001]
  • [Cites] FASEB J. 2005 Mar;19(3):311-30 [15746175.001]
  • [Cites] Exp Cell Res. 2005 Apr 15;305(1):51-62 [15777787.001]
  • [Cites] J Am Chem Soc. 2005 Mar 30;127(12):4388-96 [15783221.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):823-39 [16002369.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):66-73 [15970370.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Nitric Oxide. 2006 Mar;14(2):122-9 [16125421.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):341-9 [16507455.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):854-62 [16508635.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):295-6 [16598890.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):294-302 [16816381.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2393-5 [17023518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] Toxicol Lett. 2007 Jan 10;168(1):58-74 [17141434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2029-30 [17284585.001]
  • [Cites] Water Sci Technol. 2006;54(11-12):327-34 [17302336.001]
  • [Cites] Mutat Res. 2007 Apr 2;628(2):99-106 [17223607.001]
  • [Cites] Biomaterials. 2007 Jul;28(19):2946-58 [17379299.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2364-72 [17893867.001]
  • [Cites] Oncogene. 2008 Nov 27;27(56):7070-82 [18806824.001]
  • [Cites] Tumour Biol. 2000 Jan-Feb;21(1):11-20 [10601837.001]
  • [Cites] Toxicology. 2001 Aug 28;165(2-3):133-44 [11522371.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):869-82 [11891186.001]
  • [Cites] Proc Nutr Soc. 2002 Feb;61(1):123-30 [12002786.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Biomaterials. 2002 Sep;23(17):3757-64 [12109701.001]
  • [Cites] Toxicol In Vitro. 2002 Oct;16(5):629-35 [12206830.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):455-60 [12676598.001]
  • [Cites] J Biosci. 2003 Feb;28(1):51-5 [12682424.001]
  • [Cites] Pharmacol Ther. 2003 Jul;99(1):113-32 [12804702.001]
  • [Cites] Prog Lipid Res. 2003 Nov;42(6):463-78 [14559067.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L344-53 [14555462.001]
  • [Cites] Water Sci Technol. 2004;49(1):103-10 [14979544.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 1;37(7):916-25 [15336307.001]
  • [Cites] J Nanosci Nanotechnol. 2004 May;4(5):521-31 [15503438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1848-51 [1057174.001]
  • [Cites] Ann N Y Acad Sci. 1976;276:455-65 [1071971.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] Scand J Work Environ Health. 1987 Feb;13(1):47-51 [3495034.001]
  • (PMID = 19815711.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 15FIX9V2JP / titanium dioxide; 61512-21-8 / Thymosin; 77591-33-4 / thymosin beta(4); 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; D1JT611TNE / Titanium; G9481N71RO / Deoxyguanosine; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2774079
  •  go-up   go-down


74. Brychtova S, Bezdekova M, Brychta T, Tichy M: The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma; 2008;55(4):273-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of vascular endothelial growth factors and their receptors in malignant melanomas.
  • Vascular endothelial growth factors (VEGFs) have a leading role among variety of angiogenic factors.
  • Together with their receptors, they play an important role in endothelial cell proliferation and/or elongation, migration and vascular morphogenesis.
  • Production of both VEGFs were common in benign melanocytic tumors while MM exhibited significant upregulation of VEGF (p<0.0027) and VEGF-C (p<0.0001).
  • VEGFRs were localized in tumor, as well in stromal cells.
  • The protein expression in the tumor microenvironment highlights their importance in malignant stromal phenotype which may serve as a potential target for the anticancer therapy.
  • [MeSH-major] Melanoma / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Skin Neoplasms / metabolism. Vascular Endothelial Growth Factors / metabolism
  • [MeSH-minor] Endothelium, Vascular / metabolism. Humans. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Nestin. Prognosis. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505336.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


75. Kubo M, Ihn H, Yamane K, Tamaki K: The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans. Br J Dermatol; 2006 May;154(5):919-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are benign and intermediate malignant fibrotic dermal tumours, respectively.
  • RESULTS: We detected strong expression of TGFbeta-RI and TGFbeta-RII on epidermis and epidermal appendages, moderate expression in vascular endothelial cells, smooth muscle cells and neural tissues, and weak expression in fibroblasts in normal skin sections.
  • The expression of TGFbeta-RI and TGFbeta-RII was decreased in DFSP in comparison with DF, and their expression was found to be homogeneous in each DFSP tumour cell.
  • The staining for TGF-beta1 was found prominently on matrix and spindle-shaped tumour cells of DF, and peripheral regions of DFSP.
  • Weak expression of TGF-beta1 was found on normal skin or tumour cells in the central part of DFSP.
  • Type I collagen expression was found on spindle-shaped tumour cells in DF, but not in tumour cells of DFSP.
  • [MeSH-major] Dermatofibrosarcoma / metabolism. Histiocytoma, Benign Fibrous / metabolism. Neoplasm Proteins / metabolism. Receptors, Transforming Growth Factor beta / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Activin Receptors, Type I / genetics. Activin Receptors, Type I / metabolism. Adult. Biomarkers, Tumor / metabolism. Collagen Type I / metabolism. Diagnosis, Differential. Female. Humans. In Situ Hybridization. Male. Middle Aged. Protein-Serine-Threonine Kinases. RNA, Messenger / genetics. Skin / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Dermatofibroma.
  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634896.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


76. Lu L, Chen RG, Li XQ, Wang J: [Kimura disease and epithelioid hemangioma: a comparative study of 12 cases]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, EH appeared only as a small skin nodule or red plaque.
  • The former represents a lymphoid hyperplasia and the latter represents a benign vascular tumor.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Head and Neck Neoplasms / pathology. Hemangioma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Kimura disease.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185506.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Ki-67 Antigen; 0 / von Willebrand Factor; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


77. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • Histological picture shows networks of spindle shaped cells and vascular spaces surrounded by an endothelial cell layer.


78. Peralejo B, Beltrani V, Bielory L: Dermatologic and allergic conditions of the eyelid. Immunol Allergy Clin North Am; 2008 Feb;28(1):137-68, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topics include various eyelid dermatitis, inflammatory lesions, infections, benign and malignant tumor, urticaria, vascular lesions, and others.
  • [MeSH-major] Blepharitis / immunology. Eyelids / immunology. Hypersensitivity. Skin Diseases / immunology

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282550.001).
  • [ISSN] 0889-8561
  • [Journal-full-title] Immunology and allergy clinics of North America
  • [ISO-abbreviation] Immunol Allergy Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  •  go-up   go-down


79. Ghaemmaghami F, Karimi Zarchi M: Giant vulvar lymphangioma circumscriptum mimicking vulvar tumor: a case report and literature review. J Low Genit Tract Dis; 2007 Oct;11(4):281-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant vulvar lymphangioma circumscriptum mimicking vulvar tumor: a case report and literature review.
  • BACKGROUND: Lymphangioma circumscriptum (LC) is a benign dilation of lymph channels localized to the skin and subcutaneous tissues.
  • She underwent wide local excision, and histological examination showed multiple dilated vascular channels in papillary dermis with a diagnosis of vulvar LC.

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917576.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


80. Wu JK, Kitajewski JK: A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. J Craniofac Surg; 2009 Mar;20 Suppl 1:698-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiomas are the most common benign tumor of infancy, yet its pathogenesis and the mechanisms governing proliferation and involution are not well understood.
  • The underlying anomaly of the HemEC is not known, although studies have shown that vascular endothelial growth factor (VEGF) and VEGF signaling may influence HemECs.
  • Notch signaling has been shown to play a role during embryogenesis in directing vascular patterning and development and arterial and venous cell fate determination.
  • Postnatally, it has been implicated in tumor angiogenesis in multiple malignancies.
  • Notch signaling triggers tumor angiogenesis at least in part to stimulation by VEGF, thus establishing that there is a cross talk between the VEGF and Notch pathways.
  • Given the presence of VEGF and its receptors in hemangiomas and known VEGF-Notch cross talk in tumor angiogenesis, the authors hypothesize that Notch signaling may contribute to hemangioma proliferation and involution.
  • [MeSH-major] Hemangioma / physiopathology. Receptors, Notch / physiology. Receptors, Vascular Endothelial Growth Factor / physiology. Signal Transduction / physiology. Skin Neoplasms / physiopathology
  • [MeSH-minor] Animals. Endothelium, Vascular / cytology. Humans. Infant. Mice. Receptor Cross-Talk. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24 [17296940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3225-30 [17296941.001]
  • [Cites] Plast Reconstr Surg. 2007 Sep 15;120(4):869-78 [17805113.001]
  • [Cites] Pediatr Dermatol. 2007 Jul-Aug;24(4):353-5 [17845154.001]
  • [Cites] Pediatr Dermatol. 2007 Jul-Aug;24(4):356-62 [17845155.001]
  • [Cites] Curr Opin Lipidol. 2007 Oct;18(5):508-14 [17885420.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3369-82 [17948123.001]
  • [Cites] PLoS One. 2007;2(11):e1167 [18000539.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2664-70 [17872454.001]
  • [Cites] Expert Rev Mol Med. 2007;9(32):1-19 [18045510.001]
  • [Cites] J Am Acad Dermatol. 2008 Apr;58(4):685-90 [18342717.001]
  • [Cites] Lymphat Res Biol. 2007;5(4):237-43 [18370914.001]
  • [Cites] Lymphat Res Biol. 2007;5(4):245-55 [18370915.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4727-35 [18559519.001]
  • [Cites] Med Hypotheses. 2008 Aug;71(2):286-92 [18434035.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2592-9 [18535669.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1373-5 [14576053.001]
  • [Cites] Pediatr Dermatol. 2004 Jan-Feb;21(1):1-9 [14871317.001]
  • [Cites] Bioessays. 2004 Mar;26(3):225-34 [14988924.001]
  • [Cites] Pediatr Dev Pathol. 2003 Nov-Dec;6(6):495-510 [15018449.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):875-82 [15153887.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):341-7 [15288259.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):145-63 [15300010.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1068-79 [15143338.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6854-7 [15466172.001]
  • [Cites] Laryngoscope. 2004 Nov;114(11):1880-91 [15510009.001]
  • [Cites] Clin Pediatr (Phila). 1984 Sep;23(9):504-6 [6467784.001]
  • [Cites] Development. 1991 Sep;113(1):199-205 [1764995.001]
  • [Cites] Development. 1992 Dec;116(4):931-41 [1295745.001]
  • [Cites] J Clin Invest. 1994 Jun;93(6):2357-64 [7911127.001]
  • [Cites] Mech Dev. 1994 May;46(2):123-36 [7918097.001]
  • [Cites] Cell. 1995 Mar 24;80(6):909-17 [7697721.001]
  • [Cites] Prenat Diagn. 1995 Mar;15(3):209-14 [7784377.001]
  • [Cites] Development. 1995 Aug;121(8):2407-18 [7671806.001]
  • [Cites] Development. 1996 Jul;122(7):2251-9 [8681805.001]
  • [Cites] J Pediatr. 1996 Mar;128(3):329-35 [8774499.001]
  • [Cites] J Pediatr. 1996 Sep;129(3):346-54 [8804322.001]
  • [Cites] Dev Biol. 1996 Nov 25;180(1):370-6 [8948600.001]
  • [Cites] Oncogene. 1997 Apr 24;14(16):1883-90 [9150355.001]
  • [Cites] Development. 1997 Aug;124(16):3065-76 [9272948.001]
  • [Cites] Dev Biol. 1998 Apr 15;196(2):204-17 [9576833.001]
  • [Cites] Radiology. 1998 Jun;207(3):601-7 [9609880.001]
  • [Cites] Curr Opin Genet Dev. 1998 Aug;8(4):436-42 [9729720.001]
  • [Cites] Plast Reconstr Surg. 1999 Jan;103(1):1-9; discussion 10 [9915157.001]
  • [Cites] J Cell Physiol. 2005 Jan;202(1):230-9 [15389523.001]
  • [Cites] Mol Cell Biochem. 2004 Sep;264(1-2):99-102 [15544039.001]
  • [Cites] Lymphat Res Biol. 2003;1(4):321-30 [15624562.001]
  • [Cites] Can J Physiol Pharmacol. 2005 Jan;83(1):14-23 [15759046.001]
  • [Cites] Gene Expr Patterns. 2005 Jun;5(5):701-9 [15939383.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):13-23 [16023595.001]
  • [Cites] J Pediatr Surg. 2005 Jul;40(7):1167-72 [16034764.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8530-7 [16166334.001]
  • [Cites] Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406 [16190987.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8690-7 [16204037.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19097-102 [16365311.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1313-8 [10837024.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1343-52 [10837027.001]
  • [Cites] Curr Probl Surg. 2000 Aug;37(8):517-84 [10955029.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):745-52 [11254674.001]
  • [Cites] Arch Dermatol. 2001 May;137(5):559-70 [11346333.001]
  • [Cites] Plast Reconstr Surg. 2001 Jun;107(7):1647-54 [11391180.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2271-80 [11733376.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):295-303 [11807987.001]
  • [Cites] Ophthalmology. 2002 Apr;109(4):633-4 [11949625.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):127-36 [12110173.001]
  • [Cites] Trends Cardiovasc Med. 2002 Jul;12(5):220-4 [12161076.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):543-53 [12615665.001]
  • [Cites] Zhonghua Kou Qiang Yi Xue Za Zhi. 2003 Sep;38(5):355-7 [14680584.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:219-38 [14744245.001]
  • [Cites] Pediatrics. 2006 Mar;117(3):959-64 [16510684.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Trends Cell Biol. 2006 Jun;16(6):293-300 [16697642.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):884-8 [16847205.001]
  • [Cites] Blood. 2006 Aug 1;108(3):915-21 [16861344.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8501-10 [16951162.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):776-80 [17259973.001]
  • [Cites] J Pediatr. 2007 Mar;150(3):291-4 [17307549.001]
  • [ErratumIn] J Craniofac Surg. 2009 Sep;20(5):1629-30
  • (PMID = 19169152.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL062454
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS543366; NLM/ PMC3893793
  • [General-notes] NLM/ Original DateCompleted: 20090722
  •  go-up   go-down


81. Schrecengost JE, Tabbara S, Patterson J, Wick MR: Cutaneous mesenchymal hamartoma with mixed myogenous differentiation. J Cutan Pathol; 2006 Apr;33(4):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous mesenchymal hamartoma with mixed myogenous differentiation.
  • Collagen and vascular changes were also apparent.
  • They must be distinguished from a variety of other tumors, including juvenile rhabdomyoma, benign Triton tumor, and rhabdomyosarcoma.
  • [MeSH-major] Cell Differentiation. Dermis / pathology. Hamartoma / diagnosis. Mesoderm / pathology. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630187.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


82. Urquhart JL, Uzieblo A, Kohler S: Detection of HHV-8 in pyogenic granuloma-like Kaposi sarcoma. Am J Dermatopathol; 2006 Aug;28(4):317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma (KS) is a low-grade vascular neoplasm associated with human herpesvirus-8 (HHV-8) infection.
  • Recently, we encountered 6 KS tumors that histologically mimicked pyogenic granuloma (PG), a common benign vascular tumor of the skin that usually does not figure in the histologic differential diagnosis of KS.

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871034.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / latent nuclear antigen (LNA)
  •  go-up   go-down


83. Hoyoux C: [Vincristine treatment for management of alarming hemangiomas in infancy]. Rev Med Liege; 2008 Jan;63(1):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is the most benign vascular tumor encountered in infancy; its incidence is 10-12% at 1 year of age.
  • [MeSH-minor] Head and Neck Neoplasms / drug therapy. Humans. Infant. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303680.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  • [Number-of-references] 10
  •  go-up   go-down


84. Volmar KE, Cummings TJ, Wang WH, Creager AJ, Tyler DS, Xie HB: Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med; 2005 May;129(5):e113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell hidradenoma is a benign skin appendage tumor that may mimic conventional-type renal cell carcinoma.
  • Histologically, clear cell hidradenoma contains small ductular lumens, focal apocrine and squamoid change, and a less prominent vascular pattern than renal cell carcinoma.
  • Knowing the cytologic features of primary skin adnexal neoplasms helps distinguish them from cutaneous metastases, which are more commonly referred for fine-needle aspiration biopsy evaluation.
  • We report the rare case of a patient with renal cell carcinoma who underwent excision of an axillary clear cell hidradenoma, which was clinically suggestive of cutaneous metastatic disease.
  • [MeSH-minor] Axilla. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Mitotic Index. Neoplasm Metastasis / diagnosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859654.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Bellini A, Mattoli S: The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest; 2007 Sep;87(9):858-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies in various animal models of wound healing or fibrotic diseases have confirmed the ability of fibrocytes to differentiate into mature mesenchymal cells in vivo and have suggested a causal link between fibrocyte accumulation and ongoing tissue fibrogenesis or vascular remodeling in response to tissue damage or hypoxia.
  • Fibrocytes synthesizing new collagen or acquiring myofibroblast markers have been detected in human hypertrophic scars, in the skin of patients affected by nephrogenic systemic fibrosis, in human atherosclerotic lesions, and in pulmonary diseases characterized by repeated cycles of inflammation and repair, like asthma.
  • Similar cells also populate the stroma surrounding human benign tumors.
  • The available data indicate that human fibrocytes serve as a source of mature mesenchymal cells during reparative processes and in fibrotic disorders or stromal reactions predominantly associated with a persistent inflammatory infiltrate or with the selective recruitment of monocytes induced by ischemic changes and tumor development.
  • A deeper understanding of the mechanisms involved in fibrocyte differentiation in these pathological conditions may lead to the development of novel therapies for preventing detrimental tissue or vascular remodeling and metastatic progression of invasive tumors.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607298.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


86. de Wind A, Meert V, Chahidi N, Theunis A, Somerhausen Nde S: [Retiform haemangioendothelioma: a case report]. Ann Pathol; 2009 Dec;29(6):491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retiform haemangioendothelioma is a locally aggressive, very rarely metastasizing vascular lesion.
  • The term hemangioendothelioma should be restricted to vascular tumours of "intermediate malignancy" but has been used to designate tumours with variable histological features and clinical behaviour.
  • Spindle cell hemangio(endothelio)ma is currently regarded as a benign reactive lesion.
  • Epithelioid hemangioendothelioma is associated with a significant metastatic risk and has been included in the category of malignant vascular tumors.
  • The vascular lesions fulfilling the strict definition of hemangioendothelioma include retiform hemangioendothelioma, papillary intralymphatic angioendothelioma "Dabska's tumor", composite hemangioendothelioma and perhaps the controversial polymorphic hemangioendothelioma.
  • [MeSH-major] Hemangioendothelioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Endothelium, Vascular / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Tibia / pathology. Vascular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20005438.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34
  •  go-up   go-down


87. Amat Villegas I, Gómez Dorronsoro ML, López Caballero MC, del Llano Varela P, Pascual Piérola JI, Begoña Larrinaga M: [Metanephric stromal tumor: report of two cases and bibliographic review]. Arch Esp Urol; 2006 Jan-Feb;59(1):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metanephric stromal tumor: report of two cases and bibliographic review].
  • [Transliterated title] Tumor del estroma metanéfrico: presentación de dos casos en adultos y revisión de la literatura.
  • RESULTS: Characteristic histologic features include a proliferation of fusocellular cells with alternating cellularity that imparts a nodular appearance and onion-skin cuffing around entrapped renal tubules or vascular structures.
  • According to the 2002 ONS classification of tumours of the urinary system, they have been revised and re-classified as MST CONCLUSION: MST are pediatric benign tumors exceptionally diagnosed in adults.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568701.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 7
  •  go-up   go-down


88. Wu JK, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J, Kitajewski J: A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis; 2010 Mar;13(1):15-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Infantile hemangioma (IH) is the most common benign tumor of infancy, yet its pathogenesis is poorly understood.
  • Notch family members are known to play a role in vascular development during embryogenesis and postnatal tumor angiogenesis, yet the role of Notch signaling in the pathogenesis of IH has not been investigated.
  • RESULTS: Real-time PCR showed that Notch family gene expression in IH is distinct from placenta and skin.
  • Notch3 was localized to the interstitial cells outside of the nascent vascular channels in proliferating IH tissue sections, but became more apparent in the perivascular cells in involuting IH.
  • In summary, the pattern of Notch gene expression mirrors the progression from immature cells to endothelial-lined vascular channels (i.e., endothelial differentiation) that characterizes the growth and involution of IH.

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19097-102 [16365311.001]
  • [Cites] Lymphat Res Biol. 2005;3(4):234-9 [16379593.001]
  • [Cites] Blood. 2006 Aug 1;108(3):915-21 [16861344.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1083-7 [17183323.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3369-82 [17948123.001]
  • [Cites] Lymphat Res Biol. 2007;5(4):245-55 [18370915.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4727-35 [18559519.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2592-9 [18535669.001]
  • [Cites] FEBS Lett. 2008 Aug 20;582(19):2957-64 [18671974.001]
  • [Cites] Oncogene. 2008 Sep 1;27(38):5132-7 [18758482.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1236-46 [18931684.001]
  • [Cites] Circ Res. 2009 Feb 27;104(4):466-75 [19150886.001]
  • [Cites] J Craniofac Surg. 2009 Mar;20 Suppl 1:698-702 [19169152.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Apr 17;381(4):654-9 [19250926.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1638-49 [19349369.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1124-35 [19524514.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):11-22 [10665907.001]
  • [Cites] J Clin Invest. 2000 Mar;105(5):597-605 [10712431.001]
  • [Cites] Curr Probl Surg. 2000 Aug;37(8):517-84 [10955029.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):745-52 [11254674.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2271-80 [11733376.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):295-303 [11807987.001]
  • [Cites] Ophthalmology. 2002 Apr;109(4):633-4 [11949625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7455-60 [12032304.001]
  • [Cites] Trends Cardiovasc Med. 2002 Jul;12(5):220-4 [12161076.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:162-70 [12814948.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1373-5 [14576053.001]
  • [Cites] Bioessays. 2004 Mar;26(3):225-34 [14988924.001]
  • [Cites] Plast Reconstr Surg. 1982 Mar;69(3):412-22 [7063565.001]
  • [Cites] J Clin Invest. 1994 Jun;93(6):2357-64 [7911127.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1181-91 [8644859.001]
  • [Cites] Lymphat Res Biol. 2003;1(4):291-9 [15624557.001]
  • [Cites] Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406 [16190987.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8690-7 [16204037.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • (PMID = 20069356.001).
  • [ISSN] 1573-7209
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL096384-01; United States / NCI NIH HHS / CA / R01 CA136673; United States / NHLBI NIH HHS / HL / R01 HL096384; United States / NHLBI NIH HHS / HL / R01 HL096384-01
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins
  • [Other-IDs] NLM/ NIHMS176679; NLM/ PMC2846229
  •  go-up   go-down


89. Yang L, Robertson T, Tollesson G, Francis L, Campbell D, Winter C: An unusual presentation of a solitary benign giant neurofibroma. Case report. J Neurosurg Spine; 2009 Jul;11(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of a solitary benign giant neurofibroma. Case report.
  • Following minor trauma (scratching the skin overlying the tumor), the mass rapidly enlarged to approximately double in size over a period of 4 hours.
  • A CT scan and MR imaging confirmed an extraspinal tumor that was 15 x 11 x 11 cm, with an associated acute hematoma of similar dimensions.
  • The patient was taken to the operating room for hematoma evacuation and tumor resection.
  • Histopathological investigation identified a benign, diffuse neurofibroma with associated dysplastic blood vessels exhibiting irregular areas of tunica media and sinusoidal-like vascular channels.
  • The authors suggest that the source of the acute hemorrhage may be related to the neurofibroma-associated vascular dysplasia and the resultant increased vascular fragility.

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19569940.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Shin DK, Kim MS, Kim SW, Kim SH: A painful glomus tumor on the pulp of the distal phalanx. J Korean Neurosurg Soc; 2010 Aug;48(2):185-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A painful glomus tumor on the pulp of the distal phalanx.
  • Subsequent diagnostic evaluation with ultrasonographic imaging revealed the presence of a glomus tumor in the tender area.
  • Glomus tumors are benign, occurring in the vascular hamartomatous tubercles of the glomus body, which is a myoarterial apparatus typically found in the reticular dermis of the skin.
  • We report a case of a glomus tumor with a typical triad of symptoms, yet with a rare location : on the pulp of the ulnar aspect of the distal phalanx of the right little finger.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856673.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2941867
  • [Keywords] NOTNLM ; Finger / Glomus tumor / Pain
  •  go-up   go-down


91. Tokuyama W, Mikami T, Masuzawa M, Okayasu I: Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol; 2010 Mar;41(3):407-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiosarcoma of the skin is an extremely rare malignant tumor of vascular origin that usually arises in the scalp and face of elderly persons.
  • To clarify its characteristic features and cell cycle kinetics, we quantitatively evaluated the expression of cell cycle-related molecules and vascular endothelial growth factors using immunohistochemical staining, for comparison with 2 benign vascular tumors of the skin, the capillary hemangioma and the cavernous hemangioma.
  • Expression levels of vascular endothelial growth factor and its receptor, VEGFR-2, were highest in angiosarcomas.
  • These results suggest that not only VEGFR-2-mediated signal but also VEGFR-3-mediated signal may contribute to proliferation of vascular tumor cells as autocrine and paracrine signaling factors.
  • [MeSH-major] Head and Neck Neoplasms / metabolism. Hemangiosarcoma / metabolism. Scalp / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19913279.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


92. Arbiser JL, Bonner MY, Berrios RL: Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis. Curr Mol Med; 2009 Nov;9(8):929-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis.
  • Angiogenesis is a major factor in the development of benign, inflammatory, and malignant processes of the skin.
  • Endothelial cells are the effector cells of angiogenesis, and understanding their response to growth factors and inhibitors is critical to understanding the pathogenesis and treatment of skin disease.
  • Hemangiomas, benign tumors of endothelial cells, represent the most common tumor of childhood.
  • In our previous studies, we have found that tumor vasculature in human solid tumors expresses similarities in signaling to that of hemangiomas, making the knowledge of signaling in hemangiomas widely applicable.
  • These similarities include expression of reactive oxygen, NFkB and akt in tumor vasculature.
  • Furthermore, we have studied malignant vascular tumors, including hemangioendothelioma and angiosarcoma and have shown distinct signaling abnormalities in these tumors.
  • I hypothesize that hemangiomas, angiosarcomas, and vascular malformations represent the extremes of signaling abnormalities seen in pathogenic angiogenesis.
  • [MeSH-major] Hemangioma / blood supply. Hemangiosarcoma / blood supply. Neovascularization, Pathologic / pathology. Signal Transduction. Vascular Malformations / physiopathology


93. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R: Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res; 2007 Dec 15;67(24):11528-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endostatin, a proteolytic fragment of collagen XVIII, is a potent inhibitor of angiogenesis and tumor growth.
  • We studied the development of carcinogen-induced skin tumors in transgenic J4 mice overexpressing endostatin in their keratinocytes.
  • Unexpectedly, we did not observe any differences in tumor incidence and multiplicity between these and control mice, nor in the rate of conversion of benign papillomas to malignant squamous cell carcinomas (SCC).
  • We observed an inhibition of tumor angiogenesis by endostatin at an early stage in skin tumor development, but more strikingly, there was a significant reduction in lymphatic vessels in the papillomas and SCCs in association with elevated endostatin levels and also a significant inhibition of lymph node metastasis in the J4 mice.
  • We showed that tumor-infiltrating mast cells strongly expressed vascular endothelial growth factor-C (VEGF-C), and that the accumulation of these cells was markedly decreased in the tumors of the J4 mice.
  • Our data suggest that endostatin can inhibit tumor lymphangiogenesis by decreasing the VEGF-C levels in the tumors, apparently via inhibition of mast cell migration and adhesion, and support the view that the biological effects of endostatin are not restricted to endothelial cells because endostatin also regulates tumor-associated inflammation and differentiation, and the phenotype of epithelial tumors.
  • [MeSH-major] Endostatins / genetics. Lymphatic Metastasis / prevention & control. Neovascularization, Pathologic / prevention & control. Skin Neoplasms / blood supply. Skin Neoplasms / pathology


94. Scalvenzi M, De Natale F, Francia MG, Balato A: Dermoscopy of microvenular hemangioma: report of a case. Dermatology; 2007;215(1):69-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor cells lacked cellular atypia.
  • Microvenular hemangioma is a rare, slowly growing, benign vascular tumor.
  • Microvenular hemangioma is a benign vascular tumor with distinct dermoscopic and histopathological features which enable it to be distinguished from other vascular neoplasms.
  • [MeSH-major] Dermoscopy / methods. Hemangioma, Capillary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17587844.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


95. Chisci E, de Donato G, Setacci F, Perulli A, Galzerano G, Setacci C: A rare vascular tumour with distinctive clinical findings. J Cardiovasc Surg (Torino); 2008 Apr;49(2):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare vascular tumour with distinctive clinical findings.
  • Subungual glomus tumours are rare benign hamartomas arising from the arterial end of the glomus body (an arteriovenous shunt related to thermoregulation).
  • All these elements reinforced the assumed diagnosis of a glomic tumour.
  • Histological examination confirmed a typical glomus tumour.
  • Whenever a patient presents suffering from a reddish-purple, tender lesion, usually located at the extremities and especially in the nail bed, with paroxysmal pain and cold-sensitivity, a glomus tumour should be investigated.
  • [MeSH-major] Glomus Tumor. Nail Diseases. Skin Neoplasms. Thumb

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431344.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Dienus K, Bayat A, Gilmore BF, Seifert O: Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res; 2010 Dec;302(10):725-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keloid scars are common benign fibroproliferative reticular dermal lesions with unknown etiology and ill-defined management with high rate of recurrence post surgery.
  • The progression of keloids is characterized by increased deposition of extracellular matrix proteins, invasion into the surrounding healthy skin and inflammation.
  • Fibroblast activation protein alpha (FAP-α) and dipeptidyl peptidase IV (DPPIV) are proteases located at the plasma membrane promoting cell invasiveness and tumor growth and have been previously associated with keloid scars.
  • Therefore, in this study we analyzed in further detail the expression of FAP-α in keloid fibroblasts compared to control skin fibroblasts.
  • Dermal fibroblasts were obtained from punch-biopsies from the active margin of four keloids and four control skin samples.
  • We found an increased expression of FAP-α in keloid fibroblasts compared to control skin fibroblasts (p < 0.001).
  • FAP-α/DPPIV inhibition had no effect, (a) on the synthesis of the ECM proteins procollagen type I C-terminal peptide and fibronectin, (b) on the production of fibroblast growth factor or vascular endothelial growth factor, (c) on the expression of the proinflammatory cytokines interleukin-6 (IL-6), interleukin 8 (IL-8) or monocyte chemotactic protein-1.
  • [MeSH-minor] Adult. Cell Proliferation / drug effects. Cells, Cultured. Chemokine CCL2 / secretion. Dipeptides / pharmacology. Female. Fibroblast Growth Factors / genetics. Fibroblast Growth Factors / metabolism. Fibronectins / metabolism. Humans. Interleukin-6 / secretion. Interleukin-8 / secretion. Male. Organophosphonates / pharmacology. Peptide Fragments / metabolism. Procollagen / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20872224.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Dipeptides; 0 / Fibronectins; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Membrane Proteins; 0 / Organophosphonates; 0 / Peptide Fragments; 0 / Procollagen; 0 / Vascular Endothelial Growth Factor A; 0 / glycyl-prolyl-diphenylphosphonic acid; 0 / procollagen type I carboxy terminal peptide; 62031-54-3 / Fibroblast Growth Factors; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


97. Tatsas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, Kelley MC, Cates JM: Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma. J Cutan Pathol; 2010 Aug;37(8):901-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma.
  • Cutaneous angiosarcoma can sometimes mimic other benign and malignant lesions, thereby presenting a difficult differential diagnosis.
  • In the two cases of cutaneous angiosarcoma presented herein, extensive foamy cell alteration of tumor cells resembled a reactive xanthogranulomatous process.
  • Foamy cell angiosarcoma is an unusual and deceptively benign morphologic variant of cutaneous angiosarcoma.
  • Critical features for diagnosis include the presence of a deep, permeative, sometimes 'scaffolding' growth pattern and subtle areas of vascular formation.
  • [MeSH-major] Foam Cells / pathology. Granuloma / pathology. Head and Neck Neoplasms / pathology. Hemangiosarcoma / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175826.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


98. Vetter-Kauczok CS, Ströbel P, Bröcker EB, Becker JC: Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult! Vasc Health Risk Manag; 2008;4(1):263-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor which usually occurs in infants.
  • Microscopically, the tumor is composed of infiltrating lobulated nodules with slitlike or crescentic vessels which are poorly canalized and lined by spindle shaped endothelial cells.
  • We report a 36-year old female who developed a reddish tumor on the chest.
  • The association of KHE in a female adult with lymphangioma rather than KMS in this case supports the hypothesis that such an association may represent a benign subform of this disease in an adult and excision seems to be curative.
  • [MeSH-major] Hemangioendothelioma / pathology. Lymphangioma / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology


99. Drees R, Hünigen H, Wagner S, Schnorr J, Plendl J, Taupitz M: Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology. Vet Comp Oncol; 2008 Sep;6(3):151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
  • It was found to be 100% specific for malignant lesions and could therefore potentially be used as an additional noninvasive diagnostic tool differentiating malignant from benign lesions.
  • Qualitative and quantitative analyses for evaluation of presence and characteristics of the peripheral washout sign were accomplished, defining four centripetally distributed tumour zones (central, intermediate, peripheral and marginal).
  • Quantitative analysis revealed different enhancement profiles of the four tumour zones.
  • Histology indicated centripetally asymmetric vascularization and vascular endothelial growth factor VEGF/VEGF receptor 2 expression within the tumour tissue.
  • [MeSH-major] Contrast Media / pharmacology. Magnetic Resonance Imaging / methods. Neoplasms, Experimental / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Male. Rats. Rats, Inbred Strains. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178675.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


100. Cohn ML, Goncharuk VN, Diwan AH, Zhang PS, Shen SS, Prieto VG: Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol; 2005 Sep;32(8):533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
  • It is unknown whether claudins play a role in cutaneous melanoma.
  • Immunohistochemical studies were performed on tissue microarrays containing 19 benign melanocytic nevi (BN), 21 dysplastic nevi (DN), 23 primary malignant melanomas (MMs), and 31 metastatic melanomas (MMMs) using a polyclonal anti-claudin-1 antibody.
  • Immunoreactivity in tumor cells and associated vessels was graded by intensity and by percentage of reactive cells.
  • Tumor-associated vessels showed the following results: 11 of 19 (58%) in BN, 14 of 21 (67%) in DN, 17 of 23 (74%) in MM, and 6 of 31 (19%) in MMM.
  • A significant loss of expression was noted between MMM and all other lesions in tumor cells and associated vessels.
  • Within primary melanomas, there was a significant correlation between expression of claudin in tumor cells and Clark level/Breslow thickness.
  • Also significant was a decreased expression of claudin in tumor vessels of lesions with higher Breslow thickness or Clark level.
  • These data suggest that loss of claudin-1 may play a significant role in the acquisition of metastatic phenotype in cutaneous melanoma.
  • Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
  • [MeSH-major] Dysplastic Nevus Syndrome / metabolism. Melanoma / metabolism. Membrane Proteins / metabolism. Nevus, Pigmented / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Blood Vessels / metabolism. Blood Vessels / pathology. Claudin-1. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Neoplasm Metastasis. Phenotype. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115050.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins
  •  go-up   go-down






Advertisement